COVID-19 Clinical Trial Landscape
Data updated: May 20, 2026
2,239 clinical trials tracked since 2008
COVID-19 is an infectious disease caused by the SARS-CoV-2 virus, affecting the respiratory system and potentially leading to severe complications. As of the latest update, 2,233 clinical trials have been registered since 2008, with 184 trials currently active, encompassing studies that are recruiting, enrolling, or active but not recruiting. The active trials are distributed across different phases, with Phase 1 accounting for 42 active trials out of 543 total, Phase 2 with 99 active out of 1193 total, Phase 3 with 58 active out of 739 total, and Phase 4 with 15 active out of 176 total. This distribution indicates a strong concentration of ongoing research in Phase 2 trials. The leading industry sponsors with active trials include BioNTech SE and Novavax, each with 4 active trials, followed by ModernaTX, Inc. and Pfizer, each with 3 active trials, and ImmunityBio, Inc. with 2 active trials.
179 active
/
2239 total (since 2008)
41
Phase 1 Active
546 total
97
Phase 2 Active
1195 total
55
Phase 3 Active
739 total
15
Phase 4 Active
177 total
Top Industry Sponsors
Sorted by active Active Done Failed
BioNTech SE 4 22 1
Novavax 4 14 3
Pfizer 4 10 6
ModernaTX, Inc. 3 20 1
ImmunityBio, Inc. 2 2 7
+ 10 more sponsors — see full table below
Featured Phase 3 Trials
NCT06631287 RECRUITING
Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID
Wes Ely n=550
NCT06291857 ACTIVE NOT RECRUITING
A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine
Novavax n=9,320
NCT06679140 RECRUITING
A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease
Pfizer n=2,330
NCT07013474 RECRUITING
A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised
Pfizer n=300
NCT06667700 RECRUITING
A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)
Merck Sharp & Dohme LLC n=3,082
+ 734 more Phase 3 trials — see full database below
COVID-19 — Trials Started by Year (last 10 years)
2016 3
2017 2
2018 3
2019 2
2020 1,060
2021 580
2022 276
2023 156
2024 77
2025 60
2026 19
TheraRadar.com
Full Trial Database
Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.
Top Sponsors (all-time)
BioNTech SE 27
Novavax 21
Pfizer 20
ModernaTX, Inc. 24
ImmunityBio, Inc. 11
WestVac Biopharma Co., Ltd. 8
Invivyd, Inc. 6
Vaxine Pty Ltd 5
CyanVac LLC 3
Celltex Therapeutics Corporation 2
Active Trials by Phase
Phase 1 41
Phase 2 97
Phase 3 55
Phase 4 15
Enrollment Size Distribution
1-50 650
51-200 668
201-500 314
501-1k 132
1k+ 225
All Industry Sponsors
Sorted by active Active Done Failed
BioNTech SE 4 22 1
Novavax 4 14 3
Pfizer 4 10 6
ModernaTX, Inc. 3 20 1
ImmunityBio, Inc. 2 2 7
WestVac Biopharma Co., Ltd. 2 4 2
Invivyd, Inc. 2 2 2
Vaxine Pty Ltd 2 3 0
CyanVac LLC 2 1 0
Celltex Therapeutics Corporation 2 0 0
Merck 1 3 4
Sinocelltech Ltd. 1 3 4
Sanofi 1 4 2
Cellid Co., Ltd. 1 3 1
Huahui Health 1 4 0
NCT06631287 RECRUITING
Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID
Wes Ely n=550
NCT06291857 ACTIVE NOT RECRUITING
A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine
Novavax n=9,320
NCT06679140 RECRUITING
A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease
Pfizer n=2,330
NCT07013474 RECRUITING
A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised
Pfizer n=300
NCT06907251 NOT YET RECRUITING
Dapagliflozin for Long COVID Syndrome
Ottawa Heart Institute Research Corporation n=192
NCT06667700 RECRUITING
A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)
Merck Sharp & Dohme LLC n=3,082
NCT04910269 RECRUITING
Outpatient Treatment With Anti-Coronavirus Immunoglobulin
University of Minnesota n=820
NCT05543616 ACTIVE NOT RECRUITING
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
BioNTech SE n=4,292
NCT07300839 ACTIVE NOT RECRUITING
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
BioNTech SE n=5,240
NCT06928272 RECRUITING
Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study
Douglas D. Fraser n=348
NCT05855369 RECRUITING
Study of Chemosensory Enhancement Through Neuromodulation Training (SCENT for Long COVID)
Medical University of South Carolina n=145
NCT07359482 NOT YET RECRUITING
sElective Serotonin reuPtake inhibitoRs In posT-covid After COVID-19
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) n=160
NCT07222384 ACTIVE NOT RECRUITING
A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19
BioNTech SE n=343
NCT04415060 ACTIVE NOT RECRUITING
SedAting With Volatile Anesthetics Critically Ill COVID-19 Patients in ICU: Effects On Ventilatory Parameters And Survival
Sunnybrook Health Sciences Centre n=800
NCT05926505 RECRUITING
Safety and Efficacy of Anakinra Treatment for Patients With Post Acute Covid Syndrome
Hellenic Institute for the Study of Sepsis n=182
NCT05658523 ACTIVE NOT RECRUITING
COVID-19 Booster Study in Healthy Adults in Australia
Murdoch Childrens Research Institute n=496
NCT07069309 ACTIVE NOT RECRUITING
A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 Years
BioNTech SE n=760
NCT04948203 ACTIVE NOT RECRUITING
Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis
University of Chicago n=60
NCT07280572 ENROLLING BY INVITATION
RECLAIM Adaptive Platform Trial for PCC Treatments
Janneke van de Wijgert n=1,250
NCT05619653 ACTIVE NOT RECRUITING
Myocardial Protection in Patients With Post-acute Inflammatory Cardiac Involvement Due to COVID-19
Valentina Puentmann n=279
NCT05852873 ACTIVE NOT RECRUITING
PAxlovid loNg cOvid-19 pRevention triAl With recruitMent In the Community in Norway
Haukeland University Hospital n=2,000
NCT03188796 RECRUITING
The VITDALIZE Study: Effect of High-dose Vitamin D3 on 28-day Mortality in Adult Critically Ill Patients
Medical University of Graz n=2,400
NCT04802408 ACTIVE NOT RECRUITING
SARS-Cov-2 (COVID-19) Nasal Pharyngeal and Oral Pharyngeal Wash (SNOW) Trial
Milton S. Hershey Medical Center n=171
NCT05556720 ACTIVE NOT RECRUITING
Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial
Monash University n=960
NCT07184385 NOT YET RECRUITING
A Study of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Post-COVID Condition
StemCyte, Inc. n=60
NCT05507671 ACTIVE NOT RECRUITING
The Role of BCG Vaccine in the Clinical Evolution of COVID-19 and in the Efficacy of Anti-SARS-CoV-2 Vaccines
Oswaldo Cruz Foundation n=556
NCT06960928 RECRUITING
Low Dose Sirolimus in People With Post-Acute Sequelae of COVID-19 (PASC) Long COVID-19
Icahn School of Medicine at Mount Sinai n=80
NCT05261139 RECRUITING
EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease
Pfizer n=160
NCT05614349 ACTIVE NOT RECRUITING
Canadian Adaptive Platform Trial of Treatments for COVID-19 in Community Settings
Unity Health Toronto n=797
NCT06974084 NOT YET RECRUITING
Investigating Measurable PRO Acuity Trial (IMPACT) is a Multi-Center Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Maraviroc and Atorvastatin to Improve Neurocognitive and Physical Function of Subjects With Long COVID-19/Post-Acute Sequelae of COVID-19 (PASC).
HealthBio, Inc. n=252
NCT05815485 ACTIVE NOT RECRUITING
A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Determine the Safety and Effectiveness of Azeliragon in the Treatment of Patients Hospitalized for Coronavirus Disease 2019 (COVID-19) or Pneumonia
The University of Texas Medical Branch, Galveston n=144
NCT06817096 NOT YET RECRUITING
Efficacy and Safety of Nitazoxanide 600 Mg in the Outpatient Treatment of COVID-19 and Influenza
Azidus Brasil n=340
NCT05468736 ACTIVE NOT RECRUITING
Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years
Novavax n=3,600
NCT06739720 NOT YET RECRUITING
RCT of Efficacy and Safety of CP003 on CFS/ME or Post-COVID Fatigue
The University of Hong Kong n=130
NCT05689034 RECRUITING
Multicenter Randomized Double-blind Placebo-controlled Study to Investigate Azvudine in Symptomatic Adults With COVID-19 at Increased Risk of Progressing to Severe Illness
Peking Union Medical College Hospital n=1,096
NCT03808922 RECRUITING
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
Ansun Biopharma, Inc. n=274
NCT05993325 ACTIVE NOT RECRUITING
Immunogenicity and Safety of AdCLD-CoV19-1 OMI As a Booster: a COVID-19 Preventive Vaccine in Healthy Volunteers
Cellid Co., Ltd. n=4,000
NCT05787418 ENROLLING BY INVITATION
HH-120 Nasal Spray for Post-exposure Prevention of SARS-CoV-2
Huahui Health n=1,200
NCT05148871 ACTIVE NOT RECRUITING
Australian Phase 2b Study to Assess Effect of Dose Interval on Spikogen Covid-19 Vaccine
Vaxine Pty Ltd n=200
NCT05911061 NOT YET RECRUITING
A Phase Ⅲ Clinical Trial of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell) in Booster Vaccination
WestVac Biopharma Co., Ltd. n=4,950
NCT04483960 ACTIVE NOT RECRUITING
Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial
University of Melbourne n=2,200
NCT04727424 RECRUITING
Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild Symptoms
Cardresearch n=7,819
NCT05706454 RECRUITING
Phase 2/Phase 3 Study To Evaluate The Efficacy And Safety Of Ramatroban Along With The Standard Of Care In Subjects Hospitalized For COVID Pneumonia
KARE Biosciences n=324
NCT04636697 ACTIVE NOT RECRUITING
Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults
Medicago n=30,918
NCT04709328 NOT YET RECRUITING
To Evaluate SCTA01 Treatment of High-risk Outpatients With COVID-19
Sinocelltech Ltd. n=690
NCT04351347 RECRUITING
The Efficacy of Ivermectin in Larger Doses in COVID-19 Treatment
Tanta University n=300
NCT04376034 RECRUITING
Convalescent Plasma Collection and Treatment in Pediatrics and Adults
West Virginia University n=240
NCT04326426 ENROLLING BY INVITATION
ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection
Vanda Pharmaceuticals n=300
NCT04345406 NOT YET RECRUITING
Angiotensin Converting Enzyme Inhibitors in Treatment of Covid 19
Tanta University n=60
NCT04605926 WITHDRAWN
A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19
Biocon Limited
NCT04356495 COMPLETED
Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation
University Hospital, Bordeaux n=412
NCT04516811 TERMINATED
Therapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19
South African National Blood Service n=102
NCT05204550 COMPLETED
Intranasal Heparin Treatment to Reduce Transmission Among Household Contacts of COVID 19 Positive Adults and Children
Murdoch Childrens Research Institute n=506
NCT05815498 COMPLETED
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19
ModernaTX, Inc. n=13,553
NCT05997290 COMPLETED
A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals
BioNTech SE n=1,051
NCT04510194 COMPLETED
COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)
University of Minnesota n=1,323
NCT05168813 COMPLETED
Efficacy Study of COVID-19 mRNA Vaccine in Regions With SARS-CoV-2 Variants of Concern
COVID-19 Prevention Network n=14,237
NCT04615949 TERMINATED
Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors
Cardiol Therapeutics Inc. n=90
NCT04494984 COMPLETED
A Study to Investigate the Pharmacokinetics, Efficacy and Safety of INM005 in Patients With COVID-19.
Inmunova S.A. n=243
NCT05463068 COMPLETED
Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults
Novavax n=911
NCT06128967 COMPLETED
A Multicenter, Adaptive, Randomized, doublE-blinded, Placebo-controlled Study in Participants With Long COVID-19: The REVIVE Trial
Cardresearch n=399
NCT06524739 TERMINATED
Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS
CSL Behring n=16
NCT04362124 WITHDRAWN
Performance Evaluation of BCG Vaccination in Healthcare Personnel to Reduce the Severity of COVID-19 Infection.
Universidad de Antioquia
NCT04394416 TERMINATED
Trial of Imatinib for Hospitalized Adults With COVID-19
University of Maryland, Baltimore n=21
NCT04368728 COMPLETED
Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals
BioNTech SE n=46,969
NCT05265065 COMPLETED
Evaluation of Full Versus Fractional Dose of COVID-19 Vaccine Given as a Booster for the Prevention of COVID-19 in Adults in Mongolia.
Murdoch Childrens Research Institute n=601
NCT05254990 TERMINATED
Reparixin add-on Therapy to Standard Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia
Dompé Farmaceutici S.p.A n=414
NCT05513560 COMPLETED
RECLAIM: Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine
University Health Network, Toronto n=460
NCT04412772 TERMINATED
Trial of Tocilizumab for Treatment of Severe COVID-19: ARCHITECTS
Queen's Medical Center n=20
NCT04345692 TERMINATED
A Randomized Controlled Clinical Trial: Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients
Queen's Medical Center n=17
NCT05119855 COMPLETED
Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)
Merck Sharp & Dohme LLC n=165
NCT04591210 COMPLETED
The COVID-RASi Trial (COVID-19)
Ottawa Heart Institute Research Corporation n=372
NCT04828161 TERMINATED
A Dose Finding, Efficacy and Safety Study of Ensovibep (MP0420) in Ambulatory Adult Patients With Symptomatic COVID-19
Novartis Pharmaceuticals n=407
NCT04361474 COMPLETED
Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity
Fondation Ophtalmologique Adolphe de Rothschild n=120
NCT05999435 COMPLETED
Study of LAU-7b for the Treatment of Long COVID in Adults
Laurent Pharmaceuticals Inc. n=272
NCT04442048 COMPLETED
Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure
Canadian Cancer Trials Group n=195
NCT05074420 TERMINATED
A Study of Baricitinib (LY3009104) in Children With COVID-19
Eli Lilly and Company n=6
NCT06279871 COMPLETED
Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in Adults
Arcturus Therapeutics, Inc. n=1,514
NCT06178991 COMPLETED
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.
BioNTech SE n=8,795
NCT06694389 COMPLETED
Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ���50 Years of Age
ModernaTX, Inc. n=2,457
NCT05436834 COMPLETED
A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age
ModernaTX, Inc. n=1,807
NCT04393038 TERMINATED
ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19
Abivax S.A. n=509
NCT04344379 COMPLETED
Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus
Assistance Publique - Hôpitaux de Paris n=122
NCT06042855 COMPLETED
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
Susanna Naggie, MD n=3,214
NCT05605093 TERMINATED
Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)
University of Minnesota n=602
NCT04417257 TERMINATED
Study of LAU-7b for the Treatment of Coronavirus Disease 2019 (COVID-19) Disease in Adults
Laurent Pharmaceuticals Inc. n=351
NCT04955626 COMPLETED
To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age.
BioNTech SE n=16,372
NCT05012943 COMPLETED
The ARCT-154 Self-Amplifying RNA Vaccine Efficacy Study (ARCT-154-01)
Vinbiocare Biotechnology Joint Stock Company n=19,474
NCT04545541 COMPLETED
Nebulised Heparin in Patients With Severe COVID-19
Australian National University n=57
NCT04644185 TERMINATED
The Efficacy and Safety of SCTA01 in Hospitalized Patients With Severe COVID-19
Sinocelltech Ltd. n=102
NCT04843761 COMPLETED
ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19
National Institute of Allergy and Infectious Diseases (NIAID) n=473
NCT06729606 COMPLETED
Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)
National Institute of Allergy and Infectious Diseases (NIAID) n=471
NCT06729593 COMPLETED
Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)
National Institute of Allergy and Infectious Diseases (NIAID) n=87
NCT05710783 COMPLETED
Phase II/III Study of the AVX/COVID-12 Vaccine Against COVID-19 Applied as a Booster.
Laboratorio Avi-Mex, S.A. de C.V. n=4,065
NCT05472038 COMPLETED
A Study to Learn About New COVID-19 RNA Vaccine Candidates in COVID-19 Vaccine-Experienced Healthy Individuals
BioNTech SE n=1,453
NCT05552625 WITHDRAWN
The Efficacy and Safety of TADIOS as an Adjuvant Therapy in Patients Diagnosed With Mild to Moderate COVID-19
Helixmith Co., Ltd.
NCT05109611 TERMINATED
Nitric Oxide Nasal Spray (NONS) as Prevention for Treatment of Individuals at Risk of Exposure to COVID-19 Infection
Sanotize Research and Development corp. n=1,389
NCT04553705 COMPLETED
Omega-3, Nigella Sativa, Indian Costus, Quinine, Anise Seed, Deglycyrrhizinated Licorice, Artemisinin, Febrifugine on Immunity of Patients With (COVID-19)
Beni-Suef University n=150
NCT04762680 COMPLETED
Study of Recombinant Protein Vaccines With Adjuvant as a Primary Series and as a Booster Dose Against COVID-19 in Adults 18 Years of Age and Older
Sanofi Pasteur, a Sanofi Company n=3,159
NCT05279456 COMPLETED
A Phase 3b/4 Randomised Trial of 3 Doses of Protein-based Covid-19 Vaccine (SpikoGen)
Vaxine Pty Ltd n=39
NCT05305547 COMPLETED
A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19
Shionogi n=2,093
NCT04397328 WITHDRAWN
COVID-19 PEP- High-risk Individuals in Long-term and Specialized Care - Canada
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
NCT04649151 COMPLETED
A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19
ModernaTX, Inc. n=4,328
NCT05541510 TERMINATED
Evaluating the Safety and Efficacy of AD17002 Intranasal Spray in Treating Participants With Mild to Moderate COVID-19
Advagene Biopharma Co. Ltd. n=180
NCT04405271 TERMINATED
TAF/FTC for Pre-exposure Prophylaxis of COVID-19 in Healthcare Workers (CoviPrep Study)
Hospital Italiano de Buenos Aires n=1,378
NCT05524532 COMPLETED
Effects of Immulina TM Supplements With PASC Patients
University of Mississippi Medical Center n=101
NCT05897541 COMPLETED
Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection
Shionogi n=2,387
NCT04467840 COMPLETED
Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia
RedHill Biopharma Limited n=475
NCT05946551 TERMINATED
Treatment of Long CoronaVirus Disease (COVID) (TLC) Feasibility Trial
Emory University n=5
NCT04960202 COMPLETED
EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19
Pfizer n=2,091
NCT05459532 COMPLETED
A Randomised, Multi-centre, Double-blind, Phase 3 Study to Observe the Effectiveness, Safety and Tolerability of Molnupiravir Compared to Placebo Administered Orally to High-risk Adult Outpatients With Mild COVID-19 Receiving Local Standard of Care in South Africa
University of Witwatersrand, South Africa n=59
NCT06097273 COMPLETED
A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age
ModernaTX, Inc. n=8,061
NCT05875701 COMPLETED
Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA Vaccines
Novavax n=147
NCT04870333 COMPLETED
PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V
Cambridge University Hospitals NHS Foundation Trust n=2,240
NCT04635241 COMPLETED
Inhaled Heparin for Hospitalised COVID-19 Patients
Australian National University n=485
NCT04796896 COMPLETED
A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age
ModernaTX, Inc. n=11,942
NCT05629962 COMPLETED
SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19
Atea Pharmaceuticals, Inc. n=2,285
NCT04324073 COMPLETED
Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI
Assistance Publique - Hôpitaux de Paris n=239
NCT05531149 TERMINATED
Efficacy and Safety of Trimodulin (BT588) in Subjects With CAP Including COVID-19 Pneumonia
Biotest n=107
NCT06383819 COMPLETED
Efficacy and Safety of Longidaza® for the Treatment of Patients With Residual Changes in the Lungs After COVID-19
NPO Petrovax n=392
NCT05091307 COMPLETED
A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults
Janssen Vaccines & Prevention B.V. n=861
NCT06354998 COMPLETED
A Study of an Investigational mRNA-1273.815 COVID-19 Vaccine in Previously Vaccinated Adults
ModernaTX, Inc. n=217
NCT04603924 COMPLETED
Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients
NeuroBo Pharmaceuticals Inc. n=49
NCT04979884 COMPLETED
Safety and Effectiveness of Cyclosporin in the Management of COVID19 ARDS Patients in Alexandria University Hospital
Alexandria University n=66
NCT04583995 COMPLETED
A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom
Novavax n=15,185
NCT05593770 TERMINATED
International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response
NEAT ID Foundation n=28
NCT05638633 COMPLETED
Prednisolone and Vitamin B1/6/12 in Patients With Post-Covid-Syndrome
Wuerzburg University Hospital n=321
NCT04922788 COMPLETED
Study to Evaluate the Safety, Immunogenicity, and Efficacy of Nanocovax Vaccine Against COVID-19
Nanogen Pharmaceutical Biotechnology Joint Stock Company n=13,006
NCT04904471 COMPLETED
A Global Phase III Clinical Trial of Recombinant COVID- 19 Vaccine (Sf9 Cells)
WestVac Biopharma Co., Ltd. n=39,663
NCT05648110 COMPLETED
Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study
AstraZeneca n=3,882
NCT06485752 WITHDRAWN
Phase 3 Lot Consistency Study of Trivalent Hemagglutinin Nanoparticle Influenza Vaccine
Novavax
NCT05795816 COMPLETED
Effectiveness of Testofen Compared to Placebo on Long COVID Symptoms
RDC Clinical Pty Ltd n=150
NCT03554265 COMPLETED
Brain and Gut Plasticity in Mild TBI or Post-acute COVID Syndrome Following Growth Hormone Therapy
The University of Texas Medical Branch, Galveston n=72
NCT04927065 COMPLETED
A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants
ModernaTX, Inc. n=5,161
NCT04650087 COMPLETED
COVID-19 Thrombosis Prevention Trials: Post-hospital Thromboprophylaxis
Thomas L. Ortel n=1,291
NCT05329220 COMPLETED
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2
Bavarian Nordic n=4,205
NCT04410328 COMPLETED
Aggrenox To Treat Acute Covid-19
Rutgers, The State University of New Jersey n=98
NCT04784559 TERMINATED
Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection
PharmaMar n=205
NCT05204589 COMPLETED
Heterologous Boost Immunization with an Aerosolised Ad5-nCoV After Two-dose Priming with an Inactivated SARS-CoV-2 Vaccine
Jiangsu Province Centers for Disease Control and Prevention n=10,285
NCT04386070 SUSPENDED
Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19
University of Birmingham n=6,400
NCT05022329 TERMINATED
COVID-19 Vaccine Boosters in Patients With CKD
Sunnybrook Health Sciences Centre n=273
NCT04826588 COMPLETED
Randomised Evaluation of COVID-19 Therapy (RECOVERY) in Children With PIMS-TS in Switzerland (SWISSPED-RECOVERY)
University Children's Hospital Basel n=76
NCT04573153 TERMINATED
Metabolic Cofactor Supplementation and Hydroxychloroquine Combination in Covid-19 Patients
ScandiBio Therapeutics AB n=100
NCT05354024 COMPLETED
Phase II/III Randomized Clinical Trial of Booster Dose of COVID-19 (Recombinant, Inactivated) Vaccine
Butantan Institute n=4,400
NCT04505722 COMPLETED
A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants
Janssen Vaccines & Prevention B.V. n=44,325
NCT04908722 COMPLETED
A Study to Evaluate Dose Levels of Ad26.COV2.S Administered as a Two-dose Schedule in Healthy Adults
Janssen Vaccines & Prevention B.V. n=1,609
NCT05780437 COMPLETED
AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
National Institute of Allergy and Infectious Diseases (NIAID) n=1,455
NCT04614948 COMPLETED
A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults
Janssen Vaccines & Prevention B.V. n=31,835
NCT05996744 TERMINATED
Study of Obeldesivir in Children and Adolescents With COVID-19
Gilead Sciences n=3
NCT05858515 WITHDRAWN
REVERSE-Long COVID-19 With Baricitinib Study
Vanderbilt University Medical Center
NCT04362085 COMPLETED
Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care
Unity Health Toronto n=465
NCT04447469 COMPLETED
Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation
Kiniksa Pharmaceuticals International, plc n=814
NCT04924660 COMPLETED
Novel Experimental COVID-19 Therapies Affecting Host Response
Sean Collins n=1,060
NCT05894577 COMPLETED
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm F (Montelukast)
Susanna Naggie, MD n=1,453
NCT05603052 COMPLETED
A Phase III of COVID-19 Vaccine EuCorVac-19 in Healthy Adults Aged 18 Years and Older
EuBiologics Co.,Ltd n=2,852
NCT04385264 WITHDRAWN
#StayHome: Early Hydroxychloroquine to Reduce Secondary Hospitalisation and Household Transmission in COVID-19
Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland
NCT05364671 COMPLETED
Clinical Trial of Efficacy and Safety of Raphamin in the Treatment of Coronavirus Disease 2019 in Outpatients
Materia Medica Holding n=771
NCT04625725 COMPLETED
Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult.
AstraZeneca n=5,197
NCT05112900 COMPLETED
Health Information Technology for COVID-19 Testing in Schools (SCALE-UP Counts)
University of Utah n=7,122
NCT04466241 COMPLETED
Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial
ANRS, Emerging Infectious Diseases n=294
NCT05715528 COMPLETED
Study of Obeldesivir in Nonhospitalized Participants With COVID-19
Gilead Sciences n=2,011
NCT05603143 TERMINATED
Study of Obeldesivir in Participants With COVID-19 Who Have a High Risk of Developing Serious or Severe Illness
Gilead Sciences n=468
NCT05228730 TERMINATED
Evaluation of Full Versus Fractional Doses of COVID-19 Vaccines Given as a Booster in Adults in Australia - Mongolia, Indonesia, Australia Coronavirus (MIACoV).
Murdoch Childrens Research Institute n=13
NCT05925127 COMPLETED
Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines
Novavax n=994
NCT04322682 TERMINATED
Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)
Montreal Heart Institute n=4,506
NCT06039449 COMPLETED
A Study to Investigate the Prevention of COVID-19 WithVYD222 in Adults with Immune Compromise and in Participants Aged 12 Years or Older Who Are At Risk of Exposure to SARS-CoV-2
Invivyd, Inc. n=790
NCT04754594 COMPLETED
To Evaluate the Safety, Tolerability, and Immunogenicity of BNT162b2 Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older
BioNTech SE n=726
NCT06714032 COMPLETED
Effect of Traditional Chinese Medicine of Severe COVID-19
Henan University of Traditional Chinese Medicine n=172
NCT05249790 WITHDRAWN
Anti-inflammatory Drug Algorithm for COVID-19 Home Treatment
Mario Negri Institute for Pharmacological Research
NCT05077917 TERMINATED
Cromolyn Sodium for Treatment of COVID-19 Pneumonia
Texas Tech University Health Sciences Center, El Paso n=22
NCT05894564 COMPLETED
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm E (Fluvoxamine 100)
Susanna Naggie, MD n=1,208
NCT04401475 SUSPENDED
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC Vs. Placebo + SOC in Adult Hospitalized Patients with COVID-19
Edesa Biotech Inc. n=644
NCT04379271 COMPLETED
A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)
Immunic AG n=234
NCT05271929 TERMINATED
Early High-Titre Convalescent Plasma in Clinically Vulnerable Individuals With Mild COVID-19
Deutsches Rotes Kreuz DRK-Blutspendedienst Baden-Wurttemberg-Hessen n=120
NCT05299359 COMPLETED
A Single Heterologous Booster Vaccination Study of TAK-019 in Healthy Japanese Adults (COVID-19)
Takeda n=150
NCT05501522 COMPLETED
Immunogenicity and Safety Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine(GBP510) Adjuvanted with AS03 in Adults Aged 18 Years and Older
SK Bioscience Co., Ltd. n=840
NCT04904549 COMPLETED
Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older
Sanofi Pasteur, a Sanofi Company n=23,726
NCT04421664 TERMINATED
Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP Canada)
McGill University Health Centre/Research Institute of the McGill University Health Centre n=70
NCT04575064 WITHDRAWN
An International Randomized Trial of Additional Treatments for COVID-19 in Hospitalized Patients Who Are All Receiving the Local Standard of Care - WHO-SOLIDARITY-GERMANY
Professor Dr. Bernd Mühlbauer
NCT04939428 COMPLETED
Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)
Merck Sharp & Dohme LLC n=2,441
NCT04318444 TERMINATED
Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19)
Columbia University n=10
NCT05157269 WITHDRAWN
Trial to Evaluate Nitazoxanide for Treatment of Mild COVID-19 in Subjects Not at High Risk of Severe Illness
Romark Laboratories L.C.
NCT05157243 WITHDRAWN
Trial to Evaluate Nitazoxanide for Treatment of Mild or Moderate COVID-19 in Subjects at High Risk of Severe Illness
Romark Laboratories L.C.
NCT05074888 COMPLETED
Сlinical Trial of Efficacy and Safety of Prospekta in the Treatment of Post-COVID-19 Asthenia.
Materia Medica Holding n=676
NCT04327206 COMPLETED
BCG Vaccination to Protect Healthcare Workers Against COVID-19
Murdoch Childrens Research Institute n=6,828
NCT04780061 TERMINATED
Dietary Supplements for COVID-19
The Canadian College of Naturopathic Medicine n=90
NCT04315948 COMPLETED
Trial of Treatments for COVID-19 in Hospitalized Adults
Institut National de la Santé Et de la Recherche Médicale, France n=1,552
NCT04765371 COMPLETED
Comparison Between Prednisolone and Dexamethasone on Mortality in Patients on Oxygen Therapy, with CoViD-19
Hôpital NOVO n=89
NCT04973449 COMPLETED
Phase II/III Study of AZD2816, for the Prevention of COVID-19 in Adults
AstraZeneca n=2,843
NCT06585319 COMPLETED
Pirfenidone LP or Collagen-polyvinylpyrrolidone in COVID-19
Materno-Perinatal Hospital of the State of Mexico n=36
NCT04816071 WITHDRAWN
Essential Amino Acid Supplementation in Older Adult COVID-19 Patients
University of Arkansas
NCT04381377 COMPLETED
Efficacy and Safety of Polyoxidonium® in Hospitalized Patients With Coronavirus Disease COVID-19
NPO Petrovax n=394
NCT04542330 COMPLETED
Using BCG to Protect Senior Citizens During the COVID-19 Pandemic
Bandim Health Project n=1,700
NCT06567457 WITHDRAWN
Immunogenicity and Safety Study of Monovalent Omicron XBB.1.5 Vaccine as a Booster in Adults
Clover Biopharmaceuticals AUS Pty
NCT05073718 COMPLETED
SARS-CoV-2 and Acetylsalicylic Acid (SARA)
Barcelona Institute for Global Health n=38
NCT05249829 COMPLETED
A Study to Evaluate the Immunogenicity and Safety of Omicron Variant Vaccines in Comparison With mRNA-1273 Booster Vaccine for COVID-19
ModernaTX, Inc. n=3,548
NCT05371925 COMPLETED
Endothelial Protection in Post COVID-19 Patients With Sulodexide
Centro Medico del Noroeste n=206
NCT04518410 COMPLETED
ACTIV-2: A Study for Outpatients With COVID-19
National Institute of Allergy and Infectious Diseases (NIAID) n=4,044
NCT04640038 COMPLETED
Contrast Enhanced Ultrasound in COVID-19
Children's Hospital of Philadelphia n=4
NCT05463419 COMPLETED
A Phase II/III Study of PIKA Recombinant SARS-CoV-2 Vaccine as a Booster Dose.
Yisheng Biopharma (Singapore) Pte. Ltd. n=5,860
NCT04366739 WITHDRAWN
Repurposing of Chlorpromazine in Covid-19 Treatment
Centre Hospitalier St Anne
NCT04343248 TERMINATED
Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)
Romark Laboratories L.C. n=190
NCT04695704 TERMINATED
Efficacy of Montelukast in Mild-moderate Respiratory Symptoms in Patients With Long-COVID-19:
Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina n=86
NCT04359680 COMPLETED
Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection
Romark Laboratories L.C. n=1,407
NCT05007522 COMPLETED
Ketotifen and Indomethacin Combination Treatment Clinical Trial for COVID-19
Sen-Jam Pharmaceutical n=150
NCT04390594 TERMINATED
Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal
Institut Pasteur de Dakar n=59
NCT04860297 COMPLETED
A Study to Evaluate Safety and Immunogenicity of mRNA-1273 Vaccine to Prevent COVID-19 in Adult Organ Transplant Recipients and in Healthy Adult Participants
ModernaTX, Inc. n=234
NCT05572879 COMPLETED
A Phase III Study of COVID-19 Vaccine EuCorVac-19 in Healthy Adults
EuBiologics Co.,Ltd n=2,600
NCT06197217 COMPLETED
Phase III Clinical Study Evaluating the Efficacy and Safety of WPV01 in Patients With Mild/Moderate COVID-19
Westlake Pharmaceuticals (Hangzhou) Co., Ltd. n=1,350
NCT05310084 COMPLETED
Safety and Immunogenicity of BNT162b2 Coadministered With SIIV in Adults 18 Through 64 Years of Age
BioNTech SE n=1,134
NCT06022224 TERMINATED
A 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELL VACCINE TRIAL
ImmunityBio, Inc. n=35
NCT04723537 TERMINATED
Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 Disease
RedHill Biopharma Limited n=61
NCT05381350 COMPLETED
Immunogenicity and Safety of Booster Immunization of COVID-19 Vaccine (Vero Cell), Inactivated (Omicron Variant) in Healthy People Aged 18 Years and Above
Sinovac Research and Development Co., Ltd. n=1,750
NCT05975060 COMPLETED
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
Novavax n=660
NCT04609865 TERMINATED
Impact of Intravenous Lidocaine on Clinical Outcomes of Patients With ARDS During COVID-19 Pandemia
University Hospital, Strasbourg, France n=14
NCT05813587 COMPLETED
To Evaluate the Safety and Efficacy of Meplazumab in Treatment of Post-COVID-19
Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd n=121
NCT05679479 COMPLETED
Study on the Safety and Efficacy of Meplazumab for Injection in Severe Patients With COVID-19
Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd n=108
NCT04582344 COMPLETED
Clinical Trial For SARS-CoV-2 Vaccine (COVID-19)
Health Institutes of Turkey n=10,214
NCT05716425 COMPLETED
Study to Assess the Efficacy and Safety of STI-1558 in Adult Subjects With Mild or Moderate (COVID-19)
Zhejiang ACEA Pharmaceutical Co. Ltd. n=1,218
NCT04346615 TERMINATED
Safety and Efficacy Trial of Zavegepant* Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen
Pfizer n=47
NCT04652102 COMPLETED
A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older
CureVac n=39,680
NCT04341727 TERMINATED
Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection
Washington University School of Medicine n=30
NCT04540419 COMPLETED
Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19
NPO Petrovax n=500
NCT05770466 COMPLETED
Clinical Study for the Efficacy and Safety of Ropeginterferon Alfa-2b in Moderate COVID19.
National Taiwan University Hospital n=134
NCT04427501 COMPLETED
A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness
Eli Lilly and Company n=3,307
NCT05007951 COMPLETED
Immunogenicity and Safety Study of SK SARS-CoV-2 Recombinant Nanoparticle Vaccine (GBP510) Adjuvanted With AS03 (COVID-19)
SK Bioscience Co., Ltd. n=4,036
NCT04657497 COMPLETED
A Study of FOY-305 in Patients With SARS-Cov-2 Infection (COVID-19)
Ono Pharmaceutical Co., Ltd. n=155
NCT04486313 COMPLETED
Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19
Romark Laboratories L.C. n=935
NCT04333732 COMPLETED
CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION
Washington University School of Medicine n=3,411
NCT05387317 WITHDRAWN
Evaluation of COVID-19 Vaccines Given as a Booster in Healthy Adults in Indonesia (MIACoV Indonesia)
Murdoch Childrens Research Institute
NCT04470427 COMPLETED
A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19
ModernaTX, Inc. n=30,415
NCT04913675 TERMINATED
Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19.
Vir Biotechnology, Inc. n=1,065
NCT04890626 COMPLETED
Clinical Trial to Evaluate the Efficacy of Different Treatments in Patients With COVID-19
Instituto de Investigación Hospital Universitario La Paz n=356
NCT05398848 COMPLETED
Efficacy, Safety and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell)(Recov)
Jiangsu Rec-Biotechnology Co., Ltd. n=7,623
NCT04942405 COMPLETED
Efficacy, Immunogenicity, and Safety of the Inactivated COVID-19 Vaccine (TURKOVAC) Versus the CoronaVac Vaccine
Health Institutes of Turkey n=1,290
NCT05077176 COMPLETED
Phase 3 Booster Vaccination Against COVID-19
Health Institutes of Turkey n=4,340
NCT05184101 WITHDRAWN
Inhaled Heparin for Hospitalised Patients With Coronavirus Disease 2019 (COVID-19)
Australian National University
NCT04695197 COMPLETED
Malaria as a Risk Factor for COVID-19 in Western Kenya and Burkina Faso
Liverpool School of Tropical Medicine n=143
NCT04456595 COMPLETED
Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals
Butantan Institute n=12,688
NCT05413642 WITHDRAWN
COVID-19 Algorithm Treatment at Home
Mario Negri Institute for Pharmacological Research
NCT05780541 TERMINATED
PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
National Institute of Allergy and Infectious Diseases (NIAID) n=58
NCT04431453 COMPLETED
Study of Remdesivir in Participants Below 18 Years Old With COVID-19
Gilead Sciences n=59
NCT04805671 TERMINATED
Evaluation of ADG20 for the Treatment of Mild or Moderate COVID-19
Invivyd, Inc. n=399
NCT05780463 COMPLETED
MP0420 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
National Institute of Allergy and Infectious Diseases (NIAID) n=485
NCT04516746 COMPLETED
Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults
AstraZeneca n=32,450
NCT05780424 COMPLETED
BRII-196/BRII-198 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
National Institute of Allergy and Infectious Diseases (NIAID) n=353
NCT04990466 WITHDRAWN
Phase 2b/3 Trial of VSV-ΔG SARS-CoV-2 Vaccine (BRILIFE) Against Approved Comparator Vaccine.
NeuroRx, Inc.
NCT04400058 COMPLETED
Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression
Octapharma n=207
NCT04842331 WITHDRAWN
PREvent Viral Exposure and Transmission Study: a COVID-19 (SARS-CoV-2) PEP Study (PREVENT)
Thirty Respiratory Limited
NCT04324463 COMPLETED
Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial
Population Health Research Institute n=6,667
NCT04889040 TERMINATED
Study to Evaluate the Effects of RO7496998 (AT-527) in Non-Hospitalized Adult and Adolescent Participants With Mild or Moderate COVID-19
Hoffmann-La Roche n=216
NCT04750278 TERMINATED
A Phase 2/3 Study to Evaluate FP-025 in Patients With Severe to Critical COVID 19
Foresee Pharmaceuticals Co., Ltd. n=90
NCT05780268 COMPLETED
LY3819253 (LY-CoV555) for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
National Institute of Allergy and Infectious Diseases (NIAID) n=314
NCT05780281 COMPLETED
VIR-7831 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
National Institute of Allergy and Infectious Diseases (NIAID) n=367
NCT05275933 COMPLETED
Efficacy of TCM Capsules Lian Hua Qing Wen Jiao Nang in Mild COVID-19 Patients
Singapore Chung Hwa Medical Institution n=93
NCT05783206 COMPLETED
Evaluation of Safety & Efficacy of MIR 19 ® Inhalation Solution in Patients With Mild COVID-19
National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia n=984
NCT05752201 COMPLETED
ARVAC-A New Recombinant Coronavirus Disease 2019 (COVID-19) Vaccine
Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno n=2,014
NCT04425629 TERMINATED
Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19
Regeneron Pharmaceuticals n=10,078
NCT04611802 COMPLETED
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2
Novavax n=33,000
NCT04642638 TERMINATED
Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure
Inovio Pharmaceuticals n=1,307
NCT04816643 COMPLETED
A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children
BioNTech SE n=11,837
NCT04880642 COMPLETED
A Trial to Investigate Recovery From COVID-19 With C21 in Adult Subjects
Vicore Pharma AB n=272
NCT04691908 COMPLETED
Immunogenicity, Efficacy and Safety of QazCovid-in® COVID-19 Vaccine
Research Institute for Biological Safety Problems n=3,000
NCT04588792 TERMINATED
Furosemide as Supportive Therapy for COVID-19 Respiratory Failure
Dr. John Muscedere n=40
NCT05433285 COMPLETED
Immuno-bridging Study of COVID-19 Protein Subunit Recombinant Vaccine
PT Bio Farma n=4,050
NCT05104749 COMPLETED
Homeopathic Treatment of Post-acute COVID-19 Syndrome
Southwest College of Naturopathic Medicine n=77
NCT04625972 COMPLETED
Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults
AstraZeneca n=1,131
NCT04416334 COMPLETED
PREEMPTIVE THERAPY WITH COLCHICINE IN PATIENTS OLDER THAN 60 YEARS WITH HIGH RISK OF SEVERE PNEUMONIAE DUE TO CORONAVIRUS
Instituto de Investigación Marqués de Valdecilla n=70
NCT05321394 COMPLETED
Non-inferiority Trial on Treatments in Early COVID-19
Azienda Ospedaliera Universitaria Integrata Verona n=536
NCT05894538 COMPLETED
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm D (Ivermectin 600)
Susanna Naggie, MD n=1,459
NCT05426343 COMPLETED
A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Vaccine Compared With AZD1222
Medigen Vaccine Biologics Corp. n=200
NCT05198596 COMPLETED
A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 in Adults Aged 18 Years and Above
Medigen Vaccine Biologics Corp. n=250
NCT04610801 WITHDRAWN
Evaluation of the Efficacy of Xylitol Nasal Spray Against SARS-CoV-2
Larkin Community Hospital
NCT04854486 WITHDRAWN
Impact of GSE and Xylitol (Xlear) on COVID-19 Symptoms and Time to PCR Negativisation in COVID-19 Patients
Larkin Community Hospital
NCT04858620 WITHDRAWN
A Study to Evaluate the Efficacy of Xlear vs. Placebo for Acute COVID-19 Infection
Larkin Community Hospital
NCT04992260 COMPLETED
Efficacy, Immunogenicity and Safety of COVID-19 Vaccine , Inactivated in Children and Adolescents
Sinovac Research and Development Co., Ltd. n=11,349
NCT06084351 WITHDRAWN
Phase 3 Open-Label Controlled Trial of Convalescent Plasma in Early COVID-19 Infection
Larkin Community Hospital
NCT05137418 COMPLETED
Safety and Immunogenicity of COVID-19 Vaccine, Inactivated in Healthy Population Aged From 3 to 11 Years
Sinovac Research and Development Co., Ltd. n=1,000
NCT04674189 COMPLETED
A Study to Evaluate the Safety and Immunogenicity of Vaccine CVnCoV in Healthy Adults in Germany for COVID-19
CureVac n=2,357
NCT04713176 TERMINATED
Efficacy and Safety of DWJ1248 With Remdesivir in Severe COVID-19 Patients
Daewoong Pharmaceutical Co. LTD. n=240
NCT05683600 TERMINATED
Efficacy and Safety of COVID-19 Vaccine as Booster Vaccination in Adults 18 Years of Age or Older
Guangzhou Patronus Biotech Co., Ltd. n=3,000
NCT05890586 COMPLETED
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm B (Fluvoxamine)
Susanna Naggie, MD n=1,331
NCT05242042 TERMINATED
JT001 (VV116) for the Early Treatment of COVID-19
Shanghai JunTop Biosciences Co., LTD n=381
NCT04586153 COMPLETED
Study to Assess the Effect of Meplazumab on COVID-19
Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd n=174
NCT05113784 COMPLETED
the Safety and Efficacy of Meplazumab in Patients With COVID-19
Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd n=150
NCT05679492 WITHDRAWN
Study on the Safety and Efficacy of Meplazumab for Injection Patients COVID-19
Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd
NCT05517642 COMPLETED
IH Convidecia as Second Booster Dose Against Breakthrough Infections
CanSino Biologics Inc. n=540
NCT05438498 TERMINATED
Real World Evaluation of the Effectiveness of AZD7442 for Prevention of SARS-CoV-2
MediMergent, LLC n=550
NCT04956224 COMPLETED
Safety and Immunogenicity of VLA2001 Adults Aged ≥56 Years
Valneva Austria GmbH n=306
NCT05639192 TERMINATED
Asunercept for the Treatment of Patients With Moderate to Severe COVID-19 Disease
Apogenix GmbH n=34
NCT05043350 COMPLETED
Combined Antihistaminics Therapy in COVID 19 Patients
Ain Shams University n=214
NCT05926440 WITHDRAWN
Immunogenicity and Safety Study of SCB-2023 Vaccine as a Booster in Adults
Clover Biopharmaceuticals AUS Pty
NCT04501978 COMPLETED
ACTIV-3: Therapeutics for Inpatients With COVID-19
National Institute of Allergy and Infectious Diseases (NIAID) n=2,753
NCT04362111 COMPLETED
Early Treatment of Cytokine Storm Syndrome in Covid-19
University of Alabama at Birmingham n=32
NCT05188677 COMPLETED
Immunogenicity and Safety Study of SCB-2019 Vaccine as a Booster to COVID-19 Vaccine in Adults
Clover Biopharmaceuticals AUS Pty n=1,831
NCT04534725 COMPLETED
COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial;
Peter MacCallum Cancer Centre, Australia n=441
NCT04817332 COMPLETED
STOP-COVID19: Superiority Trial Of Protease Inhibition in COVID-19
University of Dundee n=406
NCT06004375 COMPLETED
THE EFFECT OF ARGININE AND GLUTAMINE ON COVID-19 PATIENTS OUTCOME: A RANDOMIZED CLINICAL TRIAL
Universitas Sriwijaya n=20
NCT04869228 TERMINATED
A Phase 3 Randomized, Double-Blind Placebo Controlled, Multi-regional Trial to Evaluate the Efficacy and Safety of GT0918 for the Treatment of Mild to Moderate COVID-19 Male Patients
Suzhou Kintor Pharmaceutical Inc, n=380
NCT04629703 COMPLETED
Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects
Rigel Pharmaceuticals n=280
NCT05009732 TERMINATED
A Study to Evaluate the Efficacy and Safety of Proxalutamide (GT0918) in Hospitalized COVID-19 Subjects
Suzhou Kintor Pharmaceutical Inc, n=139
NCT05993143 TERMINATED
Ivermectin to Prevent SARS-CoV-2 (COVID-19) Hospitalisation in Subjects Over 50
Insud Pharma n=249
NCT05011513 TERMINATED
Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR).
Pfizer n=1,440
NCT04811664 COMPLETED
A Study of SARS CoV-2 Infection and Potential Transmission in Individuals Immunized With Moderna COVID-19 Vaccine
National Institute of Allergy and Infectious Diseases (NIAID) n=1,923
NCT05249816 COMPLETED
Phase 3 Boosting Study for the SARS-CoV-2 rS Vaccine
Cogna Technology Solutions LLC n=1,000
NCT04393246 COMPLETED
mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms
Cambridge University Hospitals NHS Foundation Trust n=454
NCT04940182 COMPLETED
A Study to Assess the Efficacy and Safety of XC221 in Patients With Mild COVID-19
RSV Therapeutics LLC n=274
NCT04487574 COMPLETED
A Study to Assess the Efficacy and Safety of XC221 in Patients With COVID-19
RSV Therapeutics LLC n=118
NCT05216497 COMPLETED
Efficacy and Safety of Ingavirin®, 90 mg Capsules in Patients With COVID-19
Valenta Pharm JSC n=233
NCT04646655 COMPLETED
Enoxaparin at Prophylactic or Therapeutic Doses in COVID-19
ASST Fatebenefratelli Sacco n=142
NCT04311697 COMPLETED
Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure
APR Applied Pharma Research s.a. n=203
NCT04508023 TERMINATED
A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection
Janssen Research & Development, LLC n=1,284
NCT04504734 TERMINATED
Bucillamine in Treatment of Patients With COVID-19
Revive Therapeutics, Ltd. n=713
NCT04723394 COMPLETED
Phase III Study of AZD7442 for Treatment of COVID-19 in Outpatient Adults
AstraZeneca n=910
NCT05135546 TERMINATED
Inhaled Recombinant Non-immunogenic Staphylokinase vs Placebo in Patients With COVID-19 - FORRIF Trial
Supergene, LLC n=4
NCT04672395 COMPLETED
A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19
Clover Biopharmaceuticals AUS Pty n=31,454
NCT05582629 COMPLETED
JT001 (VV116) for the Treatment of COVID-19
Shanghai Vinnerna Biosciences Co., Ltd. n=1,369
NCT04575597 COMPLETED
Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002)
Merck Sharp & Dohme LLC n=1,735
NCT04439071 TERMINATED
A Study to Evaluate Efficacy and Safety of PTC299 (Emvododstat) in Hospitalized Participants With Coronavirus (COVID-19)
PTC Therapeutics n=189
NCT05736874 COMPLETED
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm C (Fluticasone)
Susanna Naggie, MD n=1,407
NCT05442684 WITHDRAWN
A Study to Evaluate the Safety and Immunogenicity of Ad5-vector Based Vaccine Against Coronavirus Variants in Adults (≥18 Years) Immunized With 2 Doses of mRNA Vaccines Plus One Dose of Booster AZD1222 Vaccine
CanSino Biologics Inc.
NCT04510207 COMPLETED
A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above
China National Biotec Group Company Limited n=44,101
NCT05124561 WITHDRAWN
Study to Evaluate the inHaled Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) On the Protective-Efficacy in Adults (SeiHOPE)
CanSino Biologics Inc.
NCT04917523 COMPLETED
Immuno-bridging Study of Inactivated SARS-CoV-2 Vaccine in Healthy Population Aged 3-17 vs Aged 18 Years Old and Above
China National Biotec Group Company Limited n=1,800
NCT05084911 COMPLETED
The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients (Phase3)
Shin Poong Pharmaceutical Co. Ltd. n=1,807
NCT05169008 TERMINATED
A Study to Evaluate the Safety and Immunogenicity of Ad5-nCoV and Ad5-nCoV-IH in CoronaVac Immunized Children and Adolescents
CanSino Biologics Inc. n=91
NCT04526990 COMPLETED
Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above
CanSino Biologics Inc. n=44,247
NCT05736861 COMPLETED
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm A (Ivermectin 400)
Susanna Naggie, MD n=1,800
NCT05107375 COMPLETED
Clinical Study of Recombinant Novel Coronavirus（COVID-19） Vaccine (CHO Cell) Combined With Influenza Vaccine
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. n=299
NCT05364242 COMPLETED
VLA2001 Booster in Adult Participants After Priming With mRNA COVID-19 Vaccine and/or Natural SARS-CoV-2 Infection
Valneva Austria GmbH n=178
NCT05886829 COMPLETED
Chlorpheniramine Nasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: ACCROS-III
Dr. Ferrer BioPharma n=157
NCT05040789 WITHDRAWN
Phase 3 Study to Evaluate the Lot Consistency of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine
Medicago
NCT04920942 COMPLETED
Ivermectin Treatment Efficacy in Covid-19 High Risk Patients
Clinical Research Centre, Malaysia n=500
NCT05055427 COMPLETED
Efficacy Evaluation of Shen Cao Gan Jiang Tang on Mild and Moderate COVID-19 Patients
University of Medicine and Pharmacy at Ho Chi Minh City n=300
NCT05620160 COMPLETED
Study of RAY1216 Tablets Compared With Placebo in Patients With Mild to Moderate COVID-19
Guangdong Raynovent Biotech Co., Ltd n=1,359
NCT04542408 COMPLETED
Hamburg Edoxaban for Anticoagulation in COVID-19 Study
Universitätsklinikum Hamburg-Eppendorf n=140
NCT04472728 TERMINATED
Testing the Efficacy and Safety of BIO101 for the Prevention of Respiratory Deterioration in COVID-19 Patients
Biophytis n=238
NCT05851313 COMPLETED
Role of Vit-D Supplementation on BioNTech, Pfizer Vaccine Side Effect and Immunoglobulin G Response
Sulaimani Polytechnic University n=500
NCT04745351 TERMINATED
Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 (COVID-19)
Gilead Sciences n=249
NCT04341116 COMPLETED
Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)
I-Mab Biopharma US Limited n=149
NCT05047601 COMPLETED
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
Pfizer n=2,954
NCT05506176 COMPLETED
A Clinical Study to Evaluate the Efficacy and Safety of SIM0417 Orally Co-Administered With Ritonavir in Symptomatic Adult Participants With Mild to Moderate COVID-19
Jiangsu Simcere Pharmaceutical Co., Ltd. n=1,208
NCT04331834 COMPLETED
Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic
Barcelona Institute for Global Health n=275
NCT04612972 COMPLETED
Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru
Universidad Peruana Cayetano Heredia n=12,000
NCT04472611 COMPLETED
Colchicine/Statins for the Prevention of COVID-19 Complications (COLSTAT) Trial
Yale University n=250
NCT05096832 COMPLETED
Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Study
Livzon Pharmaceutical Group Inc. n=10,381
NCT04941105 COMPLETED
Impact of PCSK9 Inhibition on Clinical Outcome in Patients During the Inflammatory Stage of the COVID-19
Collegium Medicum w Bydgoszczy n=60
NCT04401150 COMPLETED
Lessening Organ Dysfunction With VITamin C - COVID-19
Université de Sherbrooke n=392
NCT05313035 COMPLETED
Safety and Immunogenicity Study of COVID-19 Protein Subunit Recombinant Vaccine
PT Bio Farma n=360
NCT05601167 COMPLETED
Open Multicentre Study of the Safety and Efficacy Against COVID-19 of Nirmatrelvir/Ritonavir in the Adult Population
Promomed, LLC n=264
NCT05656495 COMPLETED
Efficacy and Safety of Ambervin® and Standard Therapy in Hospitalized Patients With COVID-19
Promomed, LLC n=313
NCT04791423 COMPLETED
Study of GRAd-COV2 for the Prevention of COVID-19 in Adults
ReiThera Srl n=10,300
NCT04732949 COMPLETED
Study to Assess Efficacy and Safety of Inhaled Interferon-β Therapy for COVID-19
Synairgen Research Ltd. n=623
NCT05012787 TERMINATED
Safety and Immunogenicity of Adjuvanted SARS-CoV-2 (SCB-2019) Vaccine in Adults With Chronic Immune-Mediated Diseases
Clover Biopharmaceuticals AUS Pty n=1
NCT05193279 WITHDRAWN
Safety and Immunogenicity of SCB-2019 in Children <18 Years of Age
Clover Biopharmaceuticals AUS Pty
NCT05449405 COMPLETED
Chlorpheniramine Nasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: ACCROS-I
Dr. Ferrer BioPharma n=101
NCT04371107 SUSPENDED
Proactive Care of Ambulatory COVID19 Patients
Centre Hospitalier Universitaire, Amiens n=11
NCT04806113 COMPLETED
COVID-19 Vaccine in Immunosuppressed Adults With Autoimmune Diseases
McGill University Health Centre/Research Institute of the McGill University Health Centre n=220
NCT04864561 COMPLETED
COV-COMPARE Immunogenicity of Vaccine VLA2001 Compared to AZD1222
Valneva Austria GmbH n=4,034
NCT05246137 COMPLETED
A Phase III Trial to Assess the Safety and Immunogenicity of a HIPRA's Candidate Booster Vaccination Against COVID-19.
Hipra Scientific, S.L.U n=2,646
NCT04330638 COMPLETED
Treatment of COVID-19 Patients With Anti-interleukin Drugs
University Hospital, Ghent n=342
NCT05283954 WITHDRAWN
Use of a Combined Regimen of Fluoxetine, Prednisolone and Ivermectin in the Treatment of Mild COVID-19 to Prevent Disease Progression Progression in Papua New Guinea
Oriol Mitja
NCT04613271 COMPLETED
Efficacy and Safety of Favipiravir in Covid-19 Patients in Indonesia
Ina-Respond n=130
NCT04847661 COMPLETED
Efficacy of Mefloquine as Prophylaxis Against COVID-19: A Placebo-control, Randomized Clinical Trial
Helwan University n=137
NCT04684550 WITHDRAWN
Use of Hypochlorous Acid as Prophylaxis in Health Personnel at High Risk of Infection by SARS-CoV 2 (COVID19)
Hospital Universitario San Ignacio
NCT04332107 TERMINATED
Azithromycin for COVID-19 Treatment in Outpatients Nationwide
Thomas M. Lietman n=263
NCT05048940 WITHDRAWN
Efficacy, Safety, and Immunogenicity of Vaccine Reimmunization With a Third Homologous Versus Heterologous Dose Against COVID-19 in Patients Undergoing Solid Organ Transplantation.
Instituto de Investigación Marqués de Valdecilla
NCT04328285 TERMINATED
Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers
Centre Hospitalier Universitaire de Saint Etienne n=118
NCT05007678 COMPLETED
Targeting de Novo Pyrimidine Biosynthesis by Leflunomide for the Treatment of COVID-19 Virus Disease
Ashford and St. Peter's Hospitals NHS Trust n=178
NCT04672564 TERMINATED
Study to Evaluate Safety and Efficacy of Carrimycin for Treatment of Severe Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients
Shenyang Tonglian Group CO., Ltd n=93
NCT04492358 TERMINATED
Treatment for Moderate/Severe COVID-19 in a Fragile and Vulnerable Population, Admitted to a Geriatric Hospital Unit or in a Transicional Care Center
Maria Joyera Rodríguez n=54
NCT04655586 COMPLETED
Assessing Safety, Hospitalization and Efficacy of rNAPc2 in COVID-19
ARCA Biopharma, Inc. n=160
NCT04421508 TERMINATED
A Study to Assess Pulsed Inhaled Nitric Oxide vs Placebo in Subjects With Mild or Moderate COVID-19
Bellerophon Pulse Technologies n=191
NCT04606563 TERMINATED
Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection?
University of British Columbia n=341
NCT05722691 COMPLETED
Study for Efficacy and Safety Assessment of the Drug RADAMIN®VIRO for COVID-19 Postexposure Prophylaxis
Promomed, LLC n=800
NCT05115019 WITHDRAWN
A Clinical Trial to Evaluate the Efficacy of RUTI® to Reduce the Severity of SARS-CoV-2 Infection (COVID-19)
PT. Innovative Pharma Solutions
NCT04377711 COMPLETED
A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 Patients
Covis Pharma S.à.r.l. n=400
NCT05545683 WITHDRAWN
Safety and Immunogenicity of Inactivated Heterologous Booster Vaccination
Centro de Estudios en Infectogía Pediatrica
NCT05279235 TERMINATED
Efficacy and Safety of JT001 (VV116) Compared With Favipiravir
Shanghai Vinnerna Biosciences Co., Ltd. n=290
NCT04317040 COMPLETED
Efprezimod Alfa (CD24Fc, MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007)
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) n=234
NCT05715944 COMPLETED
Incidence of COVID-19 Following Vaccination in Botswana Against SARS CoV 2
Botswana Harvard AIDS Institute Partnership n=10,888
NCT05156632 WITHDRAWN
Efficacy,Immunogenicity and Safety of COVID-19 Vaccine , Inactivated Booster Dose in Adults Aged 18 Years and Above
Sinovac Research and Development Co., Ltd.
NCT04891133 TERMINATED
EU SolidAct: An Adaptive Pandemic and Emerging Infection Platform Trial
Oslo University Hospital n=290
NCT05142527 WITHDRAWN
Study to Evaluate the Safety and Efficacy of a Monoclonal Antibody Cocktail for the Prevention of COVID-19
Alachua Government Services, Inc.
NCT05137795 WITHDRAWN
Inhaled ZYESAMI (Aviptadil Acetate) for Treatment of Severe COVID-19
APR Applied Pharma Research s.a.
NCT04360096 TERMINATED
Inhaled ZYESAMI™ (Aviptadil Acetate) for the Treatment of Severe COVID-19
APR Applied Pharma Research s.a. n=144
NCT04651790 COMPLETED
Efficacy, Safety, and Immunogenicity of Two Vaccination Schedules of an Inactivated Vaccine Against COVID-19 in Adults
Pontificia Universidad Catolica de Chile n=2,300
NCT04928430 TERMINATED
Efficacy and Safety of XAV-19 for the Treatment of Moderate-to-severe COVID-19
Xenothera SAS n=290
NCT04501783 COMPLETED
Study of Efficacy and Safety of TL-FVP-t vs. SOC in Patients With Mild to Moderate COVID-19
R-Pharm n=168
NCT04575584 TERMINATED
Efficacy and Safety of Molnupiravir (MK-4482) in Hospitalized Adult Participants With COVID-19 (MK-4482-001)
Merck Sharp & Dohme LLC n=304
NCT04327505 TERMINATED
Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19
Karolinska Institutet n=34
NCT04667780 COMPLETED
Study to Investigate the Treatment Effect of Colchicine in Patients With COVID-19
Ayub Teaching Hospital n=102
NCT05668065 COMPLETED
Immunogenicity of Heterologous Versus Homologous Prime Boost Schedule With mRNA and Inactivated COVID-19 Vaccines
Institut Pasteur de Tunis n=199
NCT04830943 COMPLETED
Cerebrolycin for Treatment of Covid-related Anosmia and Ageusia
Assiut University n=250
NCT04822818 COMPLETED
EFFICACY and SAFETY OF BEVACIZUMAB (ZIRABEV®) IN PATIENTS WITH SEVERE HYPOXEMIC COVID-19
Assistance Publique - Hôpitaux de Paris n=96
NCT04816669 COMPLETED
A Study to Evaluate Safety, Tolerability, & Immunogenicity of Multiple Formulations of BNT162b2 Against COVID-19 in Healthy Adults
BioNTech SE n=629
NCT04713553 COMPLETED
A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants
BioNTech SE n=1,574
NCT04887948 COMPLETED
Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2
Pfizer n=570
NCT04721535 TERMINATED
A Study of DWJ1248 in Prevention of COVID-19 Infection After the Exposure of SARS-COV-2
Daewoong Pharmaceutical Co. LTD. n=9
NCT05305456 COMPLETED
Clinical Trial Scheme of Tanreqing Capsules in the Treatment of COVID-19
Jiangsu Famous Medical Technology Co., Ltd. n=480
NCT04729595 TERMINATED
Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients.
Adamis Pharmaceuticals Corporation n=248
NCT04467086 COMPLETED
Propranolol as an Anxiolytic to Reduce the Use of Sedatives From Critically-ill Adults Receiving Mechanical Ventilation
Ottawa Hospital Research Institute n=72
NCT04847141 TERMINATED
A Study to Evaluate the Safety and Efficacy of C19-IG 20% in SARS-CoV-2 Infected Asymptomatic Ambulatory Outpatients
Grifols Therapeutics LLC n=465
NCT04707703 TERMINATED
Isavuconazole for the Prevention of COVID-19-associated Pulmonary Aspergillosis
Jeffrey Jenks, MD, MPH n=8
NCT04545060 COMPLETED
VIR-7831 for the Early Treatment of COVID-19 in Outpatients
Vir Biotechnology, Inc. n=1,057
NCT04362176 COMPLETED
Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults
Vanderbilt University Medical Center n=974
NCT04824365 COMPLETED
Sodium Pyruvate Nasal Spray Treatment of COVID-19 Infection
Cellular Sciences, inc. n=30
NCT04600999 COMPLETED
Clinical Trial of Favipiravir Treatment of Patients With COVID-19
University of Pecs n=14
NCT05599919 COMPLETED
Nitric Oxide Nasal Spray (NONS) To Treat and Prevent the Exacerbation of Infection in Individuals With Mild COVID-19
Sanotize Research and Development corp. n=306
NCT04668950 COMPLETED
Fluvoxamine for Early Treatment of Covid-19 (Stop Covid 2)
Washington University School of Medicine n=670
NCT04441398 WITHDRAWN
Efficacy and Safety of Nitazoxanide 600 mg to Treat Mild Ambulatory COVID-19 Patients
Azidus Brasil
NCT05595824 COMPLETED
Open Multicenter Study for Assessment of Efficacy and Safety of Molnupiravir in Adult Patients With COVID-19
Promomed, LLC n=240
NCT05231603 TERMINATED
Ivermectin for Post Exposure Prophylaxis of Covid-19
Clinical Research Centre, Malaysia n=50
NCT05231590 COMPLETED
Immunogenicity and Safety of the SpikoGen COVID-19 Vaccine in Children Aged 5 to <12 Years and 12 to <18 Years Compared With Adults Aged 18 to 40 Years
Cinnagen n=581
NCT05175625 COMPLETED
Immunogenicity and Safety of a Booster Dose of the SpikoGen COVID-19 Vaccine
Cinnagen n=300
NCT05005559 COMPLETED
Phase III Clinical Trial of CinnaGen COVID-19 Vaccine (SpikoGen)
Cinnagen n=16,876
NCT05567471 COMPLETED
Phase 3 Study to Evaluate Immunogenicity and Safety of BBV154 Booster Dose
Bharat Biotech International Limited n=875
NCT05011526 COMPLETED
A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 Against COVID-19 in Adults
Medigen Vaccine Biologics Corp. n=1,030
NCT04539275 TERMINATED
VA CoronavirUs Research and Efficacy Studies-1
VA Office of Research and Development n=75
NCT04734873 TERMINATED
CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients
Corvus Pharmaceuticals, Inc. n=46
NCT05341609 COMPLETED
Efficacy and Safety of JT001 (VV116) Compared With Paxlovid
Vigonvita Life Sciences n=822
NCT05249777 COMPLETED
A Phase III, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of TD0069 Capsule for Patients With Mild to Moderate COVID-19
Sao Thai Duong Joint Stock Company n=573
NCT04641195 COMPLETED
Vitamin D and Zinc Supplementation for Improving Treatment Outcomes Among COVID-19 Patients in India
Harvard School of Public Health (HSPH) n=181
NCT04516941 TERMINATED
CorONa Virus edoxabaN ColchicinE (CONVINCE) COVID-19
Insel Gruppe AG, University Hospital Bern n=60
NCT04680949 COMPLETED
suPAR-Guided Anakinra Treatment for Management of Severe Respiratory Failure by COVID-19
Hellenic Institute for the Study of Sepsis n=606
NCT04389840 TERMINATED
Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure
Jazz Pharmaceuticals n=27
NCT04537806 TERMINATED
A Study of Brexanolone for Acute Respiratory Distress Syndrome (ARDS) Due to Coronavirus Disease 2019 (COVID-19)
Sage Therapeutics n=29
NCT04643678 COMPLETED
Anakinra in the Management of COVID-19 Infection
Hamad Medical Corporation n=80
NCT05033145 COMPLETED
Study on Safety and Clinical Efficacy of AZVUDINE in Initial Stage COVID-19 Patients (SARS-CoV-2 Infected)
HRH Pharmaceuticals Limited n=312
NCT04668235 COMPLETED
Study on Safety and Clinical Efficacy of AZVUDINE in COVID-19 Patients (SARS-CoV-2 Infected)
HRH Pharmaceuticals Limited n=180
NCT04354428 TERMINATED
Treatment for COVID-19 in High-Risk Adult Outpatients
University of Washington n=289
NCT04345289 TERMINATED
Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia
Thomas Benfield n=147
NCT04581915 TERMINATED
PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19
Wits Health Consortium (Pty) Ltd n=74
NCT04724629 COMPLETED
Survival TRial Using CytoKines in COVID-19 (STRUCK Trial)
University of Sao Paulo n=60
NCT04421027 COMPLETED
A Study of Baricitinib (LY3009104) in Participants With COVID-19
Eli Lilly and Company n=1,525
NCT04822701 TERMINATED
A Study to Test BI 767551 in People With Mild to Moderate Symptoms of COVID-19
Boehringer Ingelheim n=5
NCT05205759 TERMINATED
Non-inferiority Trial on Monoclonal Antibodies in COVID-19
Azienda Ospedaliera Universitaria Integrata Verona n=319
NCT05224856 WITHDRAWN
To Evaluate the Safety and Efficacy of Inhaled CT-P63 and CT-P66 Combination Therapy in Symptomatic Patients With COVID-19 Not Requiring Supplemental Oxygen
Celltrion
NCT04602000 COMPLETED
A Phase 2/3 Study to Evaluate the Efficacy and Safety of CT-P59 in Patients With Mild to Moderate SARS-CoV-2 Infection
Celltrion n=1,642
NCT05461365 COMPLETED
Intranasal Insulin for COVID-19-related Smell Loss
Universidad Panamericana n=27
NCT04359953 TERMINATED
Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19
University Hospital, Strasbourg, France n=16
NCT05445089 COMPLETED
Study to Verify the Effectiveness and Safety of Isothymol or Carvacrol Compound Against SARS-CoV-2 in COVID-19 Patients
Instituto Venezolano de Investigaciones Cientificas n=600
NCT04475302 COMPLETED
BCG Vaccine in Reducing Morbidity and Mortality in Elderly Individuals in COVID-19 Hotspots
Tuberculosis Research Centre, India n=2,175
NCT04590586 COMPLETED
Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients
Amgen n=515
NCT04640168 COMPLETED
Adaptive COVID-19 Treatment Trial 4 (ACTT-4)
National Institute of Allergy and Infectious Diseases (NIAID) n=1,010
NCT05195242 COMPLETED
The Effect of Dexamethasone 12 mg vs 6 mg on Thromboembolic Events in Patients With Critical COVID-19
Karolinska Institutet n=445
NCT04341441 TERMINATED
Will Hydroxychloroquine Impede or Prevent COVID-19
Henry Ford Health System n=624
NCT04521296 TERMINATED
Efficacy and Safety of DWJ1248 in Patients With Mild to Moderate COVID-19 Compared to the Placebo
Daewoong Pharmaceutical Co. LTD. n=432
NCT05417997 COMPLETED
Effect of Kunamin in SARS-CoV-2 RT-PCR Positive Covid-19 Patients
RAAS Nutritionals, LLC n=71
NCT04636034 TERMINATED
The Effect of Ganglion Sphenopalatine Block Versus Placebo on Persistent Headache Following COVID-19 Infection
University Hospital Bispebjerg and Frederiksberg n=18
NCT04350593 COMPLETED
Dapagliflozin in Respiratory Failure in Patients With COVID-19
Saint Luke's Health System n=1,250
NCT04435795 TERMINATED
Inhaled Ciclesonide for Outpatients With COVID19
McGill University Health Centre/Research Institute of the McGill University Health Centre n=215
NCT04655625 COMPLETED
Phase II / III Study of COVID-19 DNA Vaccine (AG0302-COVID19)
AnGes, Inc. n=500
NCT04328441 COMPLETED
Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine
UMC Utrecht n=1,511
NCT04460183 COMPLETED
A Study to Assess Efficacy and Safety of RESP301 Plus Standard of Care (SOC) Compared to SOC Alone in Hospitalized Participants With COVID-19
Thirty Respiratory Limited n=19
NCT04400799 TERMINATED
Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With COVID-19
University of Zurich n=475
NCT04567173 TERMINATED
Convalescent Plasma as Adjunctive Therapy for Hospitalized Patients With COVID-19
University of the Philippines n=44
NCT04673162 COMPLETED
Evaluation of the Efficacy of High Doses of Methylprednisolone in SARS-CoV2 ( COVID-19) Pneumonia Patients
Azienda USL Reggio Emilia - IRCCS n=260
NCT04636671 COMPLETED
Methylprednisolone vs. Dexamethasone in COVID-19 Pneumonia (MEDEAS RCT)
University of Trieste n=690
NCT04800224 COMPLETED
Brazilian Green Propolis Extract (EPP-AF) as an Adjunct Treatment for Hospitalized COVID-19 Patients (BeeCovid2)
D'Or Institute for Research and Education n=200
NCT04860258 TERMINATED
COVID-19: A Study to Evaluate Safety, Reactogenicity and Immunogenicity of the SARS-CoV-2 mRNA Vaccine CVnCoV in Adults With Co-morbidities
CureVac n=129
NCT05029245 WITHDRAWN
IntraDermal Versus Intramuscular Comirnaty® Efficacy Study
Department of Medical Services Ministry of Public Health of Thailand
NCT04420364 WITHDRAWN
Maintenance Versus Reduction of Immunosuppression for Renal Transplant Patients Hospitalized With COVID-19 Disease
Brigham and Women's Hospital
NCT04357457 COMPLETED
Efficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to Covid-19-related Pneumonia
Assistance Publique - Hôpitaux de Paris n=181
NCT04492254 TERMINATED
Early Prophylactic Low-molecular-weight Heparin (LMWH) in Symptomatic COVID-19 Positive Patients
Thrombosis Research Institute n=219
NCT04792021 COMPLETED
Effect of N-acetylcysteine on Oxidative Stress in COVID-19 Patients
Ain Shams University n=60
NCT04439045 COMPLETED
Efficacy and Safety of VPM1002 in Reducing SARS-CoV-2 (COVID-19) Infection Rate and Severity
University Health Network, Toronto n=122
NCT04372979 TERMINATED
Efficacy of Convalescent Plasma Therapy in the Early Care of COVID-19 Patients.
Direction Centrale du Service de Santé des Armées n=18
NCT04502667 COMPLETED
Efficacy of Vitamin D Treatment in Pediatric Patients Hospitalized by COVID-19
Coordinación de Investigación en Salud, Mexico n=45
NCT04662684 COMPLETED
Medically Ill Hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis With Rivaroxaban ThErapy: The MICHELLE Trial
Science Valley Research Institute n=320
NCT04579640 COMPLETED
Trial of Vitamin D to Reduce Risk and Severity of COVID-19 and Other Acute Respiratory Infections
Queen Mary University of London n=6,200
NCT04322123 COMPLETED
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)
Hospital do Coracao n=667
NCT04546581 COMPLETED
Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC)
University of Minnesota n=593
NCT04683224 WITHDRAWN
A Study to Evaluate the Safety, Immunogenicity, and Efficacy of UB-612 COVID-19 Vaccine
Vaxxinity, Inc.
NCT04589949 TERMINATED
Early Convalescent Plasma Therapy for High-risk Patients With COVID-19 in Primary Care (the CoV-Early Study)
Erasmus Medical Center n=420
NCT04447534 COMPLETED
Zinc With Chloroquine/Hydroxychloroquine in Treatment of COVID-19
Tanta University n=191
NCT04342182 TERMINATED
Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease (CONCOVID Study)
Erasmus Medical Center n=86
NCT04649515 TERMINATED
Efficacy and Safety of TY027, a Treatment for COVID-19, in Humans
Tychan Pte Ltd. n=17
NCT04328012 TERMINATED
COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With COVID-19
Bassett Healthcare n=15
NCT04529499 TERMINATED
Clinical Trial Evaluating the Efficacy and Safety of Favipiravir in Moderate to Severe COVID-19 Patients
Dr. Reddy's Laboratories Limited n=353
NCT04600141 COMPLETED
Clinical Efficacy of Heparin and Tocilizumab in Patients With Severe COVID-19 Infection
University of Sao Paulo n=308
NCT04370236 TERMINATED
INB03 for the Treatment of Pulmonary Complications From COVID-19
Inmune Bio, Inc. n=79
NCT04780035 COMPLETED
Study of the Tolerability, Safety, Immunogenicity and Preventive Efficacy of the EpiVacCorona Vaccine for the Prevention of COVID-19
Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector" n=3,000
NCT04401579 COMPLETED
Adaptive COVID-19 Treatment Trial 2 (ACTT-2)
National Institute of Allergy and Infectious Diseases (NIAID) n=1,033
NCT04492475 COMPLETED
Adaptive COVID-19 Treatment Trial 3 (ACTT-3)
National Institute of Allergy and Infectious Diseases (NIAID) n=969
NCT04280705 COMPLETED
Adaptive COVID-19 Treatment Trial (ACTT)
National Institute of Allergy and Infectious Diseases (NIAID) n=1,062
NCT04324021 TERMINATED
Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.
Swedish Orphan Biovitrum n=16
NCT04496245 COMPLETED
Reducing Acute Severe Respiratory Events in Health Care Workers During the Covid-19 Pandemic With OM85
The University of Queensland n=59
NCT04871815 COMPLETED
Effects of Sodium Pyruvate Nasal Spray in COVID-19 Long Haulers.
Cellular Sciences, inc. n=22
NCT05247307 TERMINATED
Efficacy of the Infusion of Donor Plasma in COVID-19 Infection
Hospital Galdakao-Usansolo n=93
NCT04853927 WITHDRAWN
Proxalutamide Treatment for COVID-19 Patients in Intensive Care Unit
Applied Biology, Inc.
NCT04348656 TERMINATED
CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1)
Hamilton Health Sciences Corporation n=940
NCT04705844 WITHDRAWN
Study of Adalimumab or Placebo in Patients With Mild to Moderate COVID-19 (COMBAAT)
Alachua Government Services, Inc.
NCT05262309 COMPLETED
An Open-label, Randomized, Parallel-arm Study Investigating the Efficacy and Safety of Intravenous Administration of Pamrevlumab Versus Standard of Care in Patients With COVID-19
Fondazione Policlinico Universitario Agostino Gemelli IRCCS n=42
NCT05226546 COMPLETED
Effectiveness and Safety of Platelet Rich Plasma (PRP) on Persistent Olfactory Dysfunction Related to COVID-19
Centre Hospitalier Universitaire Saint Pierre n=56
NCT04509973 COMPLETED
Higher vs. Lower Doses of Dexamethasone for COVID-19 and Severe Hypoxia
Scandinavian Critical Care Trials Group n=1,000
NCT04539873 TERMINATED
Impact of Colchicine in Hospitalized Colombian Patients With COVID-19
Fundación Universitaria de Ciencias de la Salud n=128
NCT04498273 TERMINATED
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
Frank C Sciurba n=657
NCT04338698 COMPLETED
Hydroxychloroquine, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: An RCT
Shehnoor Azhar n=550
NCT04608266 TERMINATED
CAMOVID : Evaluation of Efficacy and Safety of Camostat Mesylate for the Treatment of SARS-CoV-2 Infection - COVID-19 in Ambulatory Adult Patients
Assistance Publique - Hôpitaux de Paris n=70
NCT04497987 COMPLETED
A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff
Eli Lilly and Company n=1,180
NCT04318015 COMPLETED
Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients (PHYDRA Trial)
National Institute of Respiratory Diseases, Mexico n=289
NCT04315896 COMPLETED
Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial)
National Institute of Respiratory Diseases, Mexico n=320
NCT04379336 COMPLETED
BCG Vaccination for Healthcare Workers in COVID-19 Pandemic
TASK Applied Science n=1,000
NCT04380519 COMPLETED
Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)
R-Pharm International, LLC n=372
NCT04344444 TERMINATED
Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease
LCMC Health n=22
NCT04377620 TERMINATED
Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)
Incyte Corporation n=211
NCT04864925 COMPLETED
Measurement of Viral Load Reduction in the Oral Cavity After a Regimental Use of OC Toothpaste Products
Colgate Palmolive n=46
NCT04560881 COMPLETED
Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (COVID-19)
Laboratorio Elea Phoenix S.A. n=3,000
NCT04410562 COMPLETED
Hydroxychloroquine Efficacy and Safety in Preventing SARS-CoV-2 Infection and COVID-19 Disease Severity During Pregnancy and Postpartum
Barcelona Institute for Global Health n=129
NCT05185284 COMPLETED
Randomized Multicenter Study on the Efficacy and Safety of Favipiravir for Parenteral Administration Compared to Standard of Care in Hospitalized Patients With COVID-19
Promomed, LLC n=217
NCT05185804 COMPLETED
Clinical Trial of Dimolegin (DD217) in Prevention of Thrombotic Complications in Patients With COVID-19
PharmaDiall Ltd. n=399
NCT04355364 TERMINATED
Efficacy and Safety of aerosolizedDornase Alfa Administration in Patients With COVID19 Induced ARDS (COVIDORNASE)
Fondation Ophtalmologique Adolphe de Rothschild n=77
NCT04502472 TERMINATED
Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent Plasma
Inova Health Care Services n=109
NCT04353271 TERMINATED
Trial of Hydroxychloroquine In Covid-19 Kinetics
University of South Alabama n=3
NCT04682873 COMPLETED
A Clinical Study to Assess the Efficacy and Safety of Amizon® Max in the Treatment of Moderate Covid-19, Caused by the SARS-CoV-2 Virus
Joint Stock Company "Farmak" n=592
NCT04795557 COMPLETED
Efficacy of Adaptogens in Patients With Long COVID-19
Swedish Herbal Institute AB n=100
NCT04535791 COMPLETED
Efficacy of Vitamin D Supplementation to Prevent the Risk of Acquiring COVID-19 in Healthcare Workers
Coordinación de Investigación en Salud, Mexico n=321
NCT04328961 COMPLETED
Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)
University of Washington n=943
NCT04345861 TERMINATED
Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for COVID-19 Pneumonia (COVIDOC Trial)
University Hospital, Montpellier n=7
NCT04372017 TERMINATED
Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection
Sanford Health n=1
NCT04894721 COMPLETED
Prophylaxis for COVID-19: Ivermectin in Close Contacts of COVID-19 Cases (IVERNEX-TUC)
Ministry of Public Health, Argentina n=172
NCT04382924 COMPLETED
Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease
Algernon Pharmaceuticals n=168
NCT04433013 WITHDRAWN
A Randomized Controlled Trial Assessing the Efficacy of Lianhua Qingwen as an Adjuvant Treatment in Patients With Mild Symptoms of COVID-19
Nanyang Technological University
NCT04353128 COMPLETED
Efficacy of Melatonin in the Prophylaxis of Coronavirus Disease 2019 (COVID-19) Among Healthcare Workers.
Instituto de Investigación Hospital Universitario La Paz n=450
NCT04401293 COMPLETED
Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients
Northwell Health n=257
NCT05126628 COMPLETED
The South Proxa-Rescue AndroCoV Trial Against COVID-19
Corpometria Institute n=133
NCT04584567 COMPLETED
OD-doxy-PNV-COVID-19 Old Drug " DOXY " for Prevention of New Virus " COVID-19 "
Hedi Gharsallah n=194
NCT04373733 COMPLETED
Early Intervention in COVID-19: Favipiravir Verses Standard Care
Chelsea and Westminster NHS Foundation Trust n=502
NCT04397562 COMPLETED
A Clinical Trial of the Efficacy and Safety of Levilimab (BCD-089) in Patients With Severe COVID-19
Biocad n=206
NCT04501952 TERMINATED
Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of Coronavirus Disease 2019 (COVID-19) in an Outpatient Setting
Gilead Sciences n=584
NCT05122234 COMPLETED
Mesenchymal Stem Cell Secretome In Severe Cases of COVID-19
Indonesia University n=40
NCT04894474 WITHDRAWN
A Study to Test Whether BI 767551 Can Prevent COVID-19 in People Who Have Been Exposed to SARS-CoV-2
Boehringer Ingelheim
NCT04452474 WITHDRAWN
Study of the Efficacy and Safety of a Single Administration of Olokizumab vs. Placebo in Addition to Standard Treatment in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19).
R-Pharm
NCT04464408 COMPLETED
Favipiravir Therapy in Adults With Mild COVID-19
King Abdullah International Medical Research Center n=231
NCT04909905 COMPLETED
Glutamine Supplementation and Short-term Mortality in Covid-19
Assiut University n=60
NCT04414241 COMPLETED
Hydroxychloroquine to Prevent SARS-CoV-2 Infection/COVID-19
Universidad Peruana Cayetano Heredia n=68
NCT04444700 COMPLETED
A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to (SARS-CoV-2) COVID-19 Pandemic
University of Sao Paulo General Hospital n=465
NCT04504240 COMPLETED
Role of Famotidine in the Clinical Improvement of COVID-19 Patients.
Chattogram General Hospital n=208
NCT04425915 COMPLETED
Efficacy of Convalescent Plasma Therapy in Patients With COVID-19
Institute of Liver and Biliary Sciences, India n=400
NCT04334148 COMPLETED
Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine
Adrian Hernandez n=1,360
NCT04358081 COMPLETED
Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease
Novartis Pharmaceuticals n=20
NCT04362137 COMPLETED
Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm
Novartis Pharmaceuticals n=432
NCT04373291 COMPLETED
Using BCG Vaccine to Protect Health Care Workers in the COVID-19 Pandemic
Bandim Health Project n=1,293
NCT04493359 TERMINATED
Switch of Renin-Angiotensin System Inhibitors in Patients With Covid-19
University of Sao Paulo n=18
NCT04504877 COMPLETED
Burnout and Distress preventiOn With caNnabidiol in Front-line Health Care workerS deAling wIth COVID-19
University of Sao Paulo n=120
NCT04371523 WITHDRAWN
Hydroxychloroquine to Prevent COVID-19 Disease Amongst Healthcare Workers
St. Joseph's Healthcare Hamilton
NCT04901065 COMPLETED
Xylocaine to Freeze During Unpleasant Nasopharyngeal Swabs
Evelyne D.Trottier n=88
NCT04315298 COMPLETED
Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19
Regeneron Pharmaceuticals n=1,912
NCT04348305 COMPLETED
Hydrocortisone for COVID-19 and Severe Hypoxia
Scandinavian Critical Care Trials Group n=30
NCT04460651 COMPLETED
PREPARE-IT. Prevention and Treatment of COVID19 With EPA in Subjects at Risk - Intervention Trial
Estudios Clínicos Latino América n=4,093
NCT04334928 COMPLETED
Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel
Plan Nacional sobre el Sida (PNS) n=1,002
NCT04345848 TERMINATED
Preventing COVID-19 Complications With Low- and High-dose Anticoagulation
University Hospital, Geneva n=160
NCT04552379 COMPLETED
The Containing Coronavirus Disease 19 (COVID-19) Trial
Pontificia Universidad Catolica de Chile n=1,173
NCT04909918 COMPLETED
Impact of Steroids on Inflammatory Response in Covid-19
Assiut University n=60
NCT04510493 COMPLETED
Canakinumab in Patients With COVID-19 and Type 2 Diabetes
University Hospital, Basel, Switzerland n=116
NCT04351763 COMPLETED
Amiodarone or Verapamil in COVID-19 Hospitalized Patients With Symptoms
Nicolaus Copernicus University n=804
NCT04303299 COMPLETED
Fight COVID-19 Trial
Department of Medical Services Ministry of Public Health of Thailand n=320
NCT05021016 COMPLETED
Study of the EpiVacCorona Vaccine With the Involvement of Volunteers Aged 60 Years and Above
Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector" n=150
NCT04838847 WITHDRAWN
A Study to Evaluate the Immunogenicity and Safety of the SARS-CoV-2 mRNA Vaccine CVnCoV in Elderly Adults Compared to Younger Adults for COVID-19
CureVac
NCT04350580 COMPLETED
Polyvalent Immunoglobulin in COVID-19 Related ARds
Centre Hospitalier St Anne n=146
NCT04486508 COMPLETED
Intermediate-dose vs Standard Prophylactic Anticoagulation and Statin vs Placebo in ICU Patients With COVID-19
Rajaie Cardiovascular Medical and Research Center n=600
NCT04673214 COMPLETED
Evaluation of Prognostic Modification in COVID-19 Patients in Early Intervention Treatment
Gilberto Cruz Arteaga n=114
NCT04361253 TERMINATED
Evaluation of SARS-CoV-2 (COVID-19) Antibody-containing Plasma thErapy
Brigham and Women's Hospital n=45
NCT04347980 TERMINATED
Dexamethasone Treatment for Severe Acute Respiratory Distress Syndrome Induced by COVID-19
Centre Chirurgical Marie Lannelongue n=5
NCT04359095 COMPLETED
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia
Universidad Nacional de Colombia n=650
NCT04485429 WITHDRAWN
Efficacy Assessment of Methylprednisolone and Heparin in Patients With COVID-19 Pneumonia
D'Or Institute for Research and Education
NCT04848467 WITHDRAWN
COVID-19: A Trial Studying the SARS-CoV-2 mRNA Vaccine CVnCoV to Learn About the Immune Response, the Safety, and the Degree of Typical Vaccination Reactions When CVnCoV is Given at the Same Time as a Flu Vaccine Compared to When the Vaccines Are Separately Given in Adults 60 Years of Age and Older
Bayer
NCT04330144 WITHDRAWN
Hydroxychloroquine as Post Exposure Prophylaxis for SARS-CoV-2(HOPE Trial)
Gangnam Severance Hospital
NCT04469114 COMPLETED
Tofacitinib in Hospitalized Patients With COVID-19 Pneumonia
Hospital Israelita Albert Einstein n=289
NCT04990830 COMPLETED
Effects of Low Molecular Weight Heparin Therapy With Soft-Mist Inhaler for COVID-19 Induced Hypoxemia
Istanbul University n=80
NCT04331054 TERMINATED
Protective Role of Inhaled Steroids for Covid-19 Infection
Assistance Publique - Hôpitaux de Paris n=146
NCT04432103 TERMINATED
Treatment of Severe and Critical COVID-19 Pneumonia With Convalescent Plasma
Centro Medico ABC n=6
NCT04353336 COMPLETED
Efficacay of Chloroquine or Hydroxychloroquine in COVID-19 Treatment
Tanta University n=194
NCT04981379 COMPLETED
Clinical Trial For Early SARS-CoV-2 (COVID-19) Treatment
Health Institutes of Turkey n=1,120
NCT04617483 COMPLETED
Study of the Commercial Scale SARS-CoV-2 Vaccine Against the Pilot Scale Among Adults, and Bridging Study of the Immunogenicity in Elderly Against That in Adults
Sinovac Research and Development Co., Ltd. n=1,040
NCT04372589 COMPLETED
Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC)
University of Manitoba n=1,200
NCT04278963 SUSPENDED
Yinhu Qingwen Decoction for the Treatment of Mild / Common CoVID-19
China Academy of Chinese Medical Sciences n=300
NCT04529525 COMPLETED
Ivermectin to Prevent Hospitalizations in COVID-19
Instituto de Cardiología de Corrientes n=501
NCT04328467 COMPLETED
Pre-exposure Prophylaxis for SARS-Coronavirus-2
University of Minnesota n=1,483
NCT04509999 WITHDRAWN
Bicalutamide to Block TMPRSS2 in Males With COVID-19 Infection
University of Florida
NCT04685512 COMPLETED
Effect of Tenofovir/Emtricitabine in Patients Recently Infected With SARS-COV2 (Covid-19) Discharged Home
University Hospital, Caen n=60
NCT04534803 WITHDRAWN
BCG Against Covid-19 for Prevention and Amelioration of Severity Trial (BAC to the PAST)
Harvard Medical School (HMS and HSDM)
NCT04728802 COMPLETED
Proxalutamide Treatment for Hospitalized COVID-19 Patients
Applied Biology, Inc. n=645
NCT04598594 COMPLETED
Evaluation of the Efficacy of Nicotine Patches in SARS-CoV2 (COVID-19) Infection in Intensive Care Unit Patients
Assistance Publique - Hôpitaux de Paris n=220
NCT04366960 COMPLETED
Comparison of Two Doses of Enoxaparin for Thromboprophylaxis in Hospitalized COVID-19 Patients
Niguarda Hospital n=189
NCT04451174 TERMINATED
Early Use of Corticosteroids in Non-critical Patients With COVID-19 Pneumonia
University of Chile n=60
NCT04395105 TERMINATED
Dexamethasone for COVID-19 Related ARDS: a Multicenter, Randomized Clinical Trial
Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno n=100
NCT04371978 TERMINATED
Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19
Rabin Medical Center n=64
NCT04443881 COMPLETED
Clinical Trial of the Use of Anakinra in Cytokine Storm Syndrome Secondary to Covid-19 (ANA-COVID-GEAS)
Fundacion Miguel Servet n=179
NCT04374526 COMPLETED
Early transfusIon of Convalescent Plasma in Elderly COVID-19 Patients. to Prevent Disease Progression.
Fondazione Policlinico Universitario Agostino Gemelli IRCCS n=29
NCT04483635 TERMINATED
PRevention of COVID-19 With Oral Vitamin D Supplemental Therapy in Essential healthCare Teams
St. Justine's Hospital n=34
NCT04475120 COMPLETED
Efficacy and Safety of Liposomal Lactoferrin in COVID-19 Patients With Mild-to-Moderate Disease and in COVID-19 Asymptomatic Patients
University of Rome Tor Vergata n=92
NCT04308668 COMPLETED
Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2
University of Minnesota n=1,312
NCT04420247 COMPLETED
Efficacy of Chloroquine or Hydroxychloroquine in Treating Pneumonia Caused by SARS-Cov-2 - COVID-19
Centro de Estudos e Pesquisa em Emergencias Medicas e Terapia Intensiva n=142
NCT04359511 WITHDRAWN
Efficacy and Safety of Corticosteroids in Oxygen-dependent Patients With COVID-19 Pneumonia
University Hospital, Tours
NCT04883203 COMPLETED
The Effect of Vitamin D Supplementation on COVID-19 Recovery
University of Monastir n=130
NCT04381962 COMPLETED
A Multicentre Open-label Two-arm Randomised Superiority Clinical Trial of Azithromycin Versus Usual Care In Ambulatory COVID19 (ATOMIC2)
University of Oxford n=298
NCT04346329 WITHDRAWN
Immune Monitoring of Prophylactic Effect of Hydroxychloroquine in Healthcare Providers Highly Exposed to COVID-19
Universidad Nacional de Colombia
NCT04344041 COMPLETED
COvid-19 and Vitamin D Supplementation: a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial)
University Hospital, Angers n=260
NCT04374942 TERMINATED
Does Hydroxychloroquine Before & During Patient Exposure Protect Healthcare Workers From Coronavirus?
Megan Landes n=13
NCT04328480 COMPLETED
The ECLA PHRI COLCOVID Trial. Effects of Colchicine on Moderate/High-risk Hospitalized COVID-19 Patients.
Estudios Clínicos Latino América n=1,279
NCT04365582 WITHDRAWN
OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome
Fondation Hôpital Saint-Joseph
NCT04550338 WITHDRAWN
Antiviral Effects of TXA as a Preventative Treatment Following COVID-19 Exposure
University of Alabama at Birmingham
NCT04578158 COMPLETED
Trial to Study the Adjuvant Benefits of Quercetin Phytosome in Patients With COVID-19
Liaquat University of Medical & Health Sciences n=152
NCT04853901 COMPLETED
Remdesivir Efficacy In Management Of COVID-19 Patients
Ain Shams University n=77
NCT04810728 COMPLETED
Efficacy of Psidii Guava's Extract For COVID-19
Faculty of Medicine Baiturrahmah University n=90
NCT04364022 COMPLETED
Efficacy of Pragmatic Same-day COVID-19 Ring Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland
Calmy Alexandra n=326
NCT04329195 TERMINATED
ACE Inhibitors or ARBs Discontinuation in Context of COVID-19 Pandemic
Assistance Publique - Hôpitaux de Paris n=44
NCT04477993 TERMINATED
Ruxolitinib for Acute Respiratory Disorder Syndrome Due to COVID-19
Vanderson Geraldo Rocha n=5
NCT04678739 COMPLETED
Efficacy and Safety of Remdesivir and Tociluzumab for the Management of Severe COVID-19: A Randomized Controlled Trial
M Abdur Rahim Medical College and Hospital n=205
NCT04632537 WITHDRAWN
BCG Vaccination to Prevent COVID-19
Henry M. Jackson Foundation for the Advancement of Military Medicine
NCT04816942 COMPLETED
Clinical Efficacy of Early Administration of Convalescent Plasma Among COVID-19 Cases in Egypt
Ministry of Health and Population, Egypt n=102
NCT04542213 COMPLETED
Dipeptidyl Peptidase-4 Inhibitor (DPP4i) for the Control of Hyperglycemia in Patients With COVID-19
Hospital Regional de Alta Especialidad del Bajio n=70
NCT04332991 COMPLETED
Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease
Massachusetts General Hospital n=479
NCT04340232 WITHDRAWN
Safety and Efficacy of Baricitinib for COVID-19
University of Colorado, Denver
NCT04348071 WITHDRAWN
Safety and Efficacy of Ruxolitinib for COVID-19
University of Colorado, Denver
NCT04389359 WITHDRAWN
PROphylaxis for paTiEnts at Risk of COVID-19 infecTion
Cambridge University Hospitals NHS Foundation Trust
NCT04325633 TERMINATED
Efficacy of Addition of Naproxen in the Treatment of Critically Ill Patients Hospitalized for COVID-19 Infection
Assistance Publique - Hôpitaux de Paris n=30
NCT04409483 WITHDRAWN
Evaluation of Additional Treatments for COVID-19: a Randomized Trial in Niger
Epicentre
NCT04547660 COMPLETED
Convalescent Plasma for Severe COVID-19 Patients
Hospital de Clinicas de Porto Alegre n=160
NCT04646109 COMPLETED
Ivermectin for Severe COVID-19 Management
Afyonkarahisar Health Sciences University n=66
NCT04292730 COMPLETED
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment
Gilead Sciences n=1,113
NCT04321278 COMPLETED
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)
Hospital Israelita Albert Einstein n=440
NCT04705753 COMPLETED
Assessment of the Clinical Effectiveness of a Herbal Extract (Cretan IAMA) in Patients With Viral Respiratory Infections, Including COVID-19, in Primary Healthcare Settings, and Co-assessment of Its Prophylactic Effect in People Cohabiting With These Patients
University of Crete n=20
NCT04350320 COMPLETED
Trial to Study the Benefit of Colchicine in Patients With COVID-19
Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia n=102
NCT04292899 COMPLETED
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)
Gilead Sciences n=4,891
NCT04405843 COMPLETED
Efficacy of Ivermectin in Adult Patients With Early Stages of COVID-19 (EPIC Trial)
Centro de Estudios en Infectogía Pediatrica n=476
NCT04374032 COMPLETED
Clinical Trial to Evaluate the Efficacy and Safety of an Immunomodulatory Therapy for the Treatment of Patients With Moderate to Severe COVID-19 Infection
Bosnalijek D.D n=120
NCT04494204 COMPLETED
Effect of a Combination of Treatment of Reginmune Capsule and Immunofree Tablets in the Treatment of Mild to Moderate COVID-19 Patients
PUNEET MITTAL n=100
NCT04675086 WITHDRAWN
Aralast NP With Antiviral Treatment and Standard of Care Versus Antiviral Treatment With Standard of Care in Hospitalized Patients With Pneumonia and COVID-19 Infection
Blessing Corporate Services, Inc
NCT04332835 COMPLETED
Convalescent Plasma for Patients With COVID-19: A Randomized, Single Blinded, Parallel, Controlled Clinical Study
Universidad del Rosario n=92
NCT04365231 WITHDRAWN
Hydroxychloroquine Azithromycin COVID-19 Pregnancy Trial
Hospital St. Joseph, Marseille, France
NCT04343001 WITHDRAWN
Coronavirus Response - Active Support for Hospitalised Covid-19 Patients
London School of Hygiene and Tropical Medicine
NCT04361461 WITHDRAWN
Use of Hydroxychloroquine Alone or Associated for Inpatients With SARS-CoV2 Virus (COVID-19)
Apsen Farmaceutica S.A.
NCT04349410 COMPLETED
The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol
The Camelot Foundation n=1,800
NCT04391127 COMPLETED
Hydroxychloroquine and Ivermectin for the Treatment of COVID-19 Infection
Centenario Hospital Miguel Hidalgo n=108
NCT04339816 TERMINATED
Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care With COVID-19: Randomised Controlled Trial
Frantisek Duska, MD, PhD n=3
NCT04364815 WITHDRAWN
The University of the Philippines Hydroxychloroquine PEP Against COVID-19 Trial
University of the Philippines
NCT04542694 COMPLETED
Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19
Promomed, LLC n=200
NCT04452643 WITHDRAWN
Efficacy of BACMUNE (MV130) in the Prevention of Disease Due to COVID-19 Infection in Healthcare Personnel
Inmunotek S.L.
NCT04371406 WITHDRAWN
Efficacy of Azithromycin-associated Hydroxychloroquine Therapy Given in General Practice in Early-stage Disease in COVID-19 Patients
Assistance Publique - Hôpitaux de Paris
NCT04603729 COMPLETED
Comparison of Efficacy of Dexamethasone and Methylprednisolone in Moderate to Severe Covid 19 Disease
Fatima Memorial Hospital n=100
NCT04446104 COMPLETED
A Preventive Treatment for Migrant Workers at High-risk of COVID-19
National University Hospital, Singapore n=4,257
NCT04333628 TERMINATED
Chloroquine for Mild Symptomatic and Asymptomatic COVID-19
HaEmek Medical Center, Israel n=5
NCT04500067 COMPLETED
Intravenous Immunoglobulin (IVIG, Bioven) Efficacy Assess for COVID-19 / SARS-CoV-2 Severe Pneumonia Complex Treatment
Biopharma Plasma LLC n=76
NCT04459325 COMPLETED
Tigerase® Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19
AO GENERIUM n=100
NCT04523831 COMPLETED
Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection
Dhaka Medical College n=400
NCT04342156 WITHDRAWN
Safety And Efficacy Of Hydroxychloroquine For At Risk Population (SHARP) Against COVID-19
Tan Tock Seng Hospital
NCT04325893 TERMINATED
Hydroxychloroquine Versus Placebo in COVID-19 Patients at Risk for Severe Disease
University Hospital, Angers n=259
NCT04480593 COMPLETED
The Use of Brazilian Green Propolis Extract (EPP-AF) in Patients Affected by COVID-19.
D'Or Institute for Research and Education n=120
NCT04530422 COMPLETED
Efficacy of Sofosbuvir Plus Ledipasvir in Egyptian Patients With COVID-19 Compared to Standard Treatment
Almaza Military Fever Hospital n=250
NCT04349228 WITHDRAWN
Assessment of the Efficacy and Safety of (HCQ) as a Prophylaxis for COVID19 for Health Professionals
Abderrahmane Mami Hospital
NCT04528927 WITHDRAWN
Evaluation of the Efficacy and Safety of Treatments for Patients Hospitalized for COVID-19 Infection Without Signs of Acute Respiratory Failure, in Tunisia
Abderrahmane Mami Hospital
NCT04403685 TERMINATED
Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers
Beneficência Portuguesa de São Paulo n=129
NCT04491994 COMPLETED
Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression
UNICEF n=540
NCT04360759 WITHDRAWN
Chloroquine Outpatient Treatment Evaluation for HIV-Covid-19
University of Cape Town
NCT04327401 TERMINATED
COVID-19-associated ARDS Treated With Dexamethasone: Alliance Covid-19 Brasil III
Hospital Sirio-Libanes n=299
NCT04408456 COMPLETED
Efficacy of Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19
Post Graduate Institute of Medical Education and Research, Chandigarh n=325
NCT04329611 TERMINATED
ALBERTA HOPE COVID-19 for the Prevention of Severe COVID19 Disease
Dr. Michael Hill n=148
NCT04304053 COMPLETED
Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia n=2,300
NCT04349241 COMPLETED
Efficacy and Safety of Favipiravir in Management of COVID-19
Ain Shams University n=100
NCT04363203 SUSPENDED
VA Remote and Equitable Access to COVID-19 Healthcare Delivery (VA-REACH TRIAL)
Salomeh Keyhani MD n=300
NCT04361552 WITHDRAWN
Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)
Emory University
NCT04244591 COMPLETED
Glucocorticoid Therapy for COVID-19 Critically Ill Patients With Severe Acute Respiratory Failure
Peking Union Medical College Hospital n=80
NCT02845843 COMPLETED
MERS-CoV Infection tReated With A Combination of Lopinavir /Ritonavir and Interferon Beta-1b
King Abdullah International Medical Research Center n=95
NCT04341870 SUSPENDED
Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO
Assistance Publique - Hôpitaux de Paris n=27
NCT04257656 TERMINATED
A Trial of Remdesivir in Adults With Severe COVID-19
Capital Medical University n=237
NCT04252664 SUSPENDED
A Trial of Remdesivir in Adults With Mild and Moderate COVID-19
Capital Medical University n=308
NCT04261517 COMPLETED
Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19
Shanghai Public Health Clinical Center n=30
Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only